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ABSTRACT 
 
Introduction: PDE5 inhibitors improve erections by potentiating nitric oxide (NO)-
cyclic guanosine monophosphate system. However, long-term diabetic patients have 
reduced efficacy secondary to dysfunction of NO system. The aim of this thesis was to 
investigate in-vitro effects of a PDE5 inhibitor (sildenafil), a soluble guanylate cyclase 
(sGC) activator (BAY41-2272) and an NO-releasing PDE5 inhibitor (NCX-911) on 
urogenital smooth muscle in conditions of NO deficiency. 
 
Method: The effect of these compounds was investigated on tone and electrical field 
stimulation-induced nitrergic relaxation of cavernosal (human and rabbit) and 
anococcygeal (rat) smooth muscle and compared to an NO donor (spermine-NONOate) 
and non-specific sGC activator (YC-1) in the absence/presence of inhibitor of NO 
synthesis (L-NAME) or inhibitor of sGC (ODQ). In a diabetic rat model, these 
compounds were assessed in untreated and L-NAME-treated tissues from non-diabetic 
and diabetic animals. 
 
Results: BAY41-2272 was more potent than YC-1 and spermine-NONOate at relaxing 
rabbit/human cavernosum. ODQ significantly decreased the potency of BAY41-2272 
whereas L-NAME did not. BAY41-2272 potentiated nitrergic responses and partially 
reversed the inhibition of nitrergic responses by L-NAME. 
NCX-911 and sildenafil were equally potent at relaxing rabbit and human cavernosum. In 
presence of L-NAME the potency of sildenafil decreased significantly. Both compounds 
potentiated nitrergic relaxations equally but failed to induce relaxation in the presence of 
ODQ. 
Nitrergic relaxation was significantly decreased in the diabetic rats but still potentiated by 
BAY41-2272 but not by sildenafil or NCX-911. The potencies of NCX-911 and BAY41-
2272 were unaltered but that of sildenafil was significantly reduced in the diabetic 
animals.  
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Conclusion: The rank of potency in control tissues was BAY41-2272 > NCX-11 = 
sildenafil; whereas in NO deficiency BAY 41-2272 > NCX-911 > sildenafil. Endogenous 
NO derived from nitrergic nerves is significantly decreased in diabetes. NO-releasing 
PDE5 inhibitors and sGC activators may be effective in management of diabetic erectile 
dysfunction. 
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INTRODUCTION 
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1. Introduction 
1.1 Physiology of penile erection 
  
Penile erection is a complex neurovascular event.  It is widely accepted that the degree of 
contraction of the corpus cavernosal smooth muscle is an important determinant of the 
functional state of penile flaccidity (detumescence) and of erection 
(tumescence)(Andersson and Wagner, 1995). The balance between the contractile and 
relaxant factors is known to be controlled by both central and peripheral mechanisms and 
involves the interaction of three different systems (Andersson, 2001b): 
A. The central nervous system  
B. The peripheral nervous system  
C. Vascular and cavernosal smooth muscle in the penis 
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1.1.1 The central nervous system  
  The central nervous system (CNS) coordinates incoming sensory information 
from a variety of sources which may be visual, auditory, cognitive/imaginative, tactile or 
olfactory. The central pathways integrating these inputs and controlling erectile function 
are complex and only partially understood. However, there is strong evidence to support 
the involvement of the paraventricular nucleus (PVN) and the medial pre-optic area 
(MPOA) within the hypothalamus in the control of erectile function (Giuliano and 
Rampin, 2000). The MPOA has been postulated to be an integrative centre that collects 
the input and redistributes to other structures within the CNS such as PVN (Giuliano and 
Rampin, 2000). The PVN in turn has been suggested to activate selective autonomic 
pathways that lead to erection (Giuliano and Rampin, 2000). The neurons from the PVN 
have been reported to project onto the spinal cord either directly (Luiten et al., 1985) or 
via the median forebrain bundle, pons and medulla (Steers, 1990). The descending 
pathways from PVN to the spinal cord have been reported to contain a variety of 
neurotransmitters such as oxytocin, vasopressin, encephalin and dopamine (Giuliano and 
Rampin, 2000).  
  Moreover, it has been demonstrated that the direct injection of various agents 
such as oxytocin, glutamate, nitric oxide (NO) and dopaminergic agonists into the PVN 
or direct electrical stimulation of PVN elicits episodes of penile erection(assi-Benelli et 
al., 1979;Giuliano and Rampin, 2000).  
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1.1.2. The peripheral nervous system 
Within the spinal cord, there are various specific areas which contain integral 
components of the erectile system. These are known as the “erection centres” (Figure 1). 
The thoraco-lumbar erection centre is located between T1 and L2 and gives rise to the 
sympathetic outflow pathway. This connects to the urogenital tract via the pelvic, 
cavernosal and pudendal nerves. The sacral erection centre is located between the S2 and 
S4 segments of the spinal cord and gives rise to parasympathetic outflow pathway. These 
fibres reach the penis via the pelvic, cavernosal and pudendal nerves. Furthermore, the 
penis receives dense somatic input from sensory branches of the dorsal nerve, a branch of 
the pudendal nerve (Andersson and Wagner, 1995).  
 
Figure 1: The nerve supply of the penis. From (Eardley and Sethia K, 2003) 
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The individual nerves innervating the penis may contain a number of different 
transmitters and as a result the nerves are categorized as either being adrenergic or 
cholinergic according to the predominant transmitter type present. However, non-
adrenergic non-cholinergic (NANC) neurotransmitters may be found and indeed be co-
localised with either adrenergic or cholinergic nerves. Nitric oxide (NO) is one of the 
NANC neurotransmitters which has now been widely accepted to be the major mediator 
eliciting relaxation of the penile smooth muscle (Lundberg, 1996). 
During sexual arousal, NO has been reported to be released from parasympathetic 
nerve terminals (Hedlund et al., 2000b) and these nerves are therefore called nitrergic 
nerves (Moncada et al., 1997). The released NO causes relaxation of the smooth muscle 
allowing engorgement of blood into the cavernous space and leading to erection. 
Noradrenaline released from sympathetic nerves causes contraction of the blood vessels 
and smooth muscle of the corpus cavernosum, thus leading to detumescence of the penis. 
Erection of the penis is therefore regulated by a balance between pro- and anti-erectile 
mediators (Figure 2). Studies with human corpus cavernosum, suggest that when the two 
systems are simultaneously active, the nitrergic system is dominant over the sympathetic 
system (Cellek and Moncada, 1997b).  
 23
 
Figure 2: Penile erection is regulated by two opposing systems: pro-erectile mediators such as nitric oxide 
(NO) and vasoactive intestinal peptide (VIP) and anti-erectile mediators such as noradrenaline (NA), 
endothelin-I, angiotensin II and thromboxane A2. 
 MEDIATORS OF PENILE ERECTION 
PRO ANTI 
Noradrenaline 
 Endothelin-I 
Angiotensin-II 
Thromboxane-A2 
Nitric Oxide 
VIP 
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1.1.3. Vascular and cavernosal smooth muscle in the penis 
The human penis is composed of paired corpora cavernosa and the single corpus 
spongiosum (Figure 3). The corpus cavernosum consists of a meshwork of sinusoidal 
spaces lined with endothelial cells (Andersson and Wagner, 1995;Bossart et al., 1980). In 
order for an erection to occur, relaxation of penile smooth muscle is required to allow 
blood to flow into the penile structures. The resulting increase in intra-cavernosal 
pressure leads to compression of the subtunical venules against the tunica albuginea (the 
corporeal veno-occlusive mechanism) (Andersson and Wagner, 1995).  This process 
reduces venous drainage from the corpora cavernosa and increases pressure within the 
corpora, producing an erection.  In full rigidity the intracavernous pressure reaches values 
considerably higher than systemic (systolic) blood pressure with the contribution of the 
skeletal muscles of the pelvic floor.  
 
 
Figure 3: Cross section through shaft of penis demonstrating the sinusoids, subtunical venules and tunica 
albuginea. From (Eardley and Sethia K, 2003) 
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1.1.4. Relaxant factors 
1.1.4.1 NO-sGC-cGMP pathway 
In the presence of functional adrenergic and cholinergic blockade, electrical field 
stimulation (EFS) results in relaxation of the corpus cavernosum smooth muscle. In 1990 
Ignarro et al (Ignarro et al., 1990) reported that EFS of isolated strips of rabbit corpus 
cavernosum resulted in the endogenous generation and release of NO, nitrite, and cyclic 
guanosine monophosphate (cGMP). Further studies demonstrated that the smooth muscle 
relaxation in response to EFS, in the presence of blockers of noradrenergic and 
cholinergic pathways (guanethidine and atropine respectively), was abolished by 
tetrodotoxin and potassium-induced depolarization. Furthermore, the relaxation was 
markedly inhibited by NG-nitro-L-arginine (L-NNA), oxyhemoglobin, and methylene 
blue, but was unaffected by indomethacin (Ignarro et al., 1990). These were the first 
published results to suggest that penile erection is mediated by NO generated in response 
to nonadrenergic-noncholinergic (NANC) stimulation.  
Using immuno-histochemical techniques the enzyme neuronal nitric oxide 
synthase (nNOS) was demonstrated to be present in the nerve fibres of the pelvic plexus, 
corpus cavernosum and around blood vessels (Alm et al., 1993;Burnett et al., 1993). 
Using an antibody against nNOS, labelling studies in the rat have demonstrated that 
nitrergic nerves which innervate the penis are parasympathetic post-ganglionic nerves 
(Vizzard et al., 1994) and that nNOS-positive nerves may be found in close proximity to 
the lumbo-sacral spinal cord (Anderson et al., 1993).  
It is now known that in the corpus cavernosum NO may be released from both the 
endothelium via eNOS and the nitrergic nerves via nNOS. Both nNOS and eNOS are 
activated by calcium entry into cells and binding to calmodulin associated with the 
enzyme. It has been suggested that nitrergic-derived NO is functionally more important, 
as nitrergic relaxation of corpus cavernosum has been reported not to require a functional 
endothelium after removal by either physical (Kim et al., 1991) or chemical means 
(Okamura et al., 1999). 
However, more recent evidence suggests that eNOS is critically involved in penile 
erection. It is considered to work in an integrative fashion with nNOS to produce NO 
required for penile erection. It has therefore been proposed that nNOS may initiate the 
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erectile process, whereas eNOS is involved in the maintenance of NO-dependent 
signalling, sustained NO production and maximal erection. It has also been suggested that 
eNOS may be activated by the process of viscous or shear stress in blood vessels to 
produce NO continuously (Burnett, 2004). Moreover, the phosphatidylinositol 3 kinase 
(PI3 kinase) pathway which activates the serine-threonine protein kinase Akt (PKB) has 
been shown to cause direct phosphorylation of eNOS (Dimmeler et al., 1999;Fulton et al., 
1999;Michell et al., 1999). Through this process there appears to be a reduction in the 
calcium requirement for eNOS which may in turn result in the increased production of 
NO and erection. 
Upon release from nitrergic nerves and the endothelium, NO exerts its action on 
smooth muscle cells by activating the enzyme soluble guanylate cyclase (sGC). The 
activation of sGC results in an increase in intracellular cGMP concentration (Figure 4) 
(Schmidt et al., 1993). 
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Figure 4: Nitric oxide (NO) released from nitrergic nerves and endothelium stimulates smooth muscle 
relaxation by activation of soluble guanylate cyclase (sGC), which in turn catalyses the conversion of GTP 
to the active intracellular second messenger cGMP. cGMP is then metabolized by PDE5 to inactive GMP. 
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Guanylate cyclase activity has been identified in both the soluble and particulate 
fractions in rats (Hardman and Sutherland, 1969) and other mammals (White and 
Aurbach, 1969). The activities of these enzymes were characterised (Garbers and Gray, 
1974), (Chrisman et al., 1975) and found to be due to different proteins.  
The purification of guanylate cyclase from the cytosolic compartment has 
revealed the soluble isoform to be a heterodimer composed of - and -subunits. The -
subunit has a molecular mass of 70 kDa, whereas the -subunit was reported to be 73 to 
82 kDa (Gerzer et al., 1981b;Kamisaki et al., 1986). It has been found to be expressed in 
the cytoplasm of most mammalian cells and is known to be involved in many important 
physiological functions, such as platelet aggregation inhibition, smooth muscle 
relaxation, neuronal transduction and immune modulation (Collier and Vallance, 1989).  
The further analysis of sGC has demonstrated the presence of multiple isotypes 
with different subunit compositions. The most abundant subunits isolated were 1 and 
1, which are found in many tissues (Garbers, 1979). It was found that the expression of 
1 and 1 individually yielded a protein without catalytic activity, whereas the co-
expression of these subunits yielded an enzyme which could be activated by NO 
(Buechler et al., 1991). Other subunits identified include 2 (Yuen et al., 1990), 2 
(Harteneck et al., 1991), 3 and 3 (Giuili et al., 1992). A variant of the 2-subunit, 2i, 
has an additional 31 amino acids in the catalytic domain (Behrends et al., 1995). It has 
been suggested that this may increase the ability of this enyme isoform to utilize ATP as 
a substrate and produce cAMP (Behrends et al., 1995;Koesling et al., 1988;Nakane et al., 
1990). 
It is now well established that each subunit of sGC can be divided into three 
functional domains: haem-binding, dimerization, and catalytic (Figure 5). 
The haem-binding domain is located at the N terminus of each subunit. The haem 
prosthetic group is required for activation of sGC by NO (Craven and DeRubertis, 1978), 
(Ignarro et al., 1982). 
Haem is a five-member nitrogen-containing ring in which four nitrogen atoms are 
co-ordinated with a central iron that can be either Fe2+ (ferrous or the reduced form) or 
Fe3+ (ferric or the oxidized form) (Figure 5). Studies have demonstrated that the fifth 
member of the ring in sGC is an imidazole axial ligand which is coordinated by the β1-
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subunit at His105(Stone and Marletta, 1994). Moreover, the mutation of this histidine, 
which is located near the N terminus of the β1-subunit is associated with an acquired 
inability of sGC enzyme to bind haem and an enzyme that was unresponsive to NO 
(Wedel et al., 1994). As discussed previously both α1- and β1-subunits are required to 
express basal catalytic activity and activation of sGC by NO (Buechler et al., 1991). 
These results suggest that both subunits play a role in the association of the haem with the 
enzyme.  
However, the presence of Cys78 and Cys124 in the β-subunit was found to be 
important for coordinating the haem group of sGC (Foerster et al., 1996). Cysteine 
residues are also known to be important in other haem-containing proteins such as 
cytochrome C, in which the haem is covalently bound to the protein through thio-ether 
bonds to two Cys residues.  
In contrast to other haem containing proteins, the haem in sGC has a very high 
affinity for NO (Gerzer et al., 1981b). Even in an aerobic environment, sGC prefers to 
bind NO rather than oxygen. If sGC binds oxygen, it forms a ferrous-oxy species that 
must exchange oxygen with NO to form a ferrous nitrosyl complex (Gerzer et al., 
1981a;Gerzer et al., 1981b;Gerzer et al., 1981c). Oxidation of the haem group to the 
ferric state results in the loss of enzyme activity and often a complete loss of the haem 
moiety from the protein. Thus, reducing agents such as thiols, ascorbate, or dithiothreitol 
enhance enzyme activation, presumably by maintaining the iron of the metalloporphyrin 
in the ferrous state that is sensitive to NO. Conversely, oxidising agents such as 
methylene blue inhibit enzyme activation(Ignarro et al., 1981). 
 The catalytic domain of each subunit has been demonstrated to be present at the 
C-terminus. There is reported to be a high degree of homology between the C-terminal 
regions of all subunits and with the catalytic domain of  particulate GC and the C1/C2 
catalytic domains of adenylate cyclase(Thorpe and Garbers, 1989). It is well established 
that both subunits are required to be expressed in order for cyclase activity despite the 
fact that both α and β subunits contain catalytic domains . Interestingly, the co-
expression of the C-terminal portions of α1 and β1 subunits may result in a basally active 
protein only. It has therefore been suggested that although two catalytic domains are 
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present, each sub-unit contributes specific residues to a single substrate binding and 
catalytic site(Liu et al., 1997). 
 
Between the catalytic and haem-binding domains there is an area which is thought 
to be important in mediating subunit association to form hetero-dimers. This dimerization 
domain is homologous to the dimerization domain of pGC and is located proximal to the 
catalytic domains of α and β subunits. 
 
 
 
 
Figure 5: The soluble guanylate cyclase enzyme. It is divided in to three domains: Haem binding, 
dimerization and catalytic. 
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The free radical NO has been shown to activate sGC by directly binding to form a 
ferrous-nitrosyl-haem complex. The half-life of this complex is reported to be between 4 
minutes and 3 hours in vitro studies at 20°C (Hille et al., 1979),(Sharma et al., 1978). NO 
is reported to bind to the haem ring at the 6th position thereby breaking a bond between an 
axial histidine and iron and forming a bond with the iron. Removal of the haem results in 
loss of NO responsiveness, therefore indicating that the mechanism is haem-dependent. 
Nitrergic nerve stimulation and the administration of NO donors results in an 
increase in intracellular cGMP concentrations in human and rabbit corpus cavernosum 
(Bush et al., 1992;Dahiya et al., 1993;Rajfer et al., 1992). Furthermore, analogues of 
cGMP elicit electrophysiological responses similar to nitrergic nerve stimulation or NO 
donors (Bowman and Drummond, 1984). 
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Mechanism of action of cGMP  
 
The mechanism by which an increased cGMP concentration results in smooth 
muscle relaxation is not completely understood. The proposed mechanisms include 
(Figure 6): 
1. cGMP may directly reduce Ca2+ entry into cells by inhibiting L-type Ca2+ 
channels (Lincoln, 1989). 
2. cGMP  may activate a cGMP-dependent protein kinase (PKG) (Lincoln and 
Cornwell, 1993). However, the effects are unlikely to be mediated by a cAMP-
dependent protein kinase (PKA) as in cGK-deficient mice, cGMP induced 
relaxation was completely abolished whereas cAMP-dependent relaxation was 
unaffected (Hofmann et al., 2000). 
 
The PKG may: 
a. directly inhibit voltage-gated Ca2+ channels (Clapp and Gurney, 1991). 
b. activate Ca2+-sensitive maxi K+ channels and hyperpolarize the membrane 
(Archer et al., 1994).  
c. activate the Na+/Ca2+ exchanger (Furukawa et al., 1991). 
d. activate the Ca2+-ATPase on the plasma membrane (Yoshida et al., 1991). 
e. inhibit IP3 receptor on the endoplasmic reticulum membrane either 
directly (Komalavilas and Lincoln, 1994) or indirectly by phosphorylating 
IP3 receptor-related regulatory proteins like phospholamban (Cornwell et 
al., 1991) or IRAG (Schlossmann et al., 2000).  
f. inhibit agonist-induced production of IP3 by binding to PIP2 (Hirata et al., 
1990). 
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Figure 6: Schematic representation of proposed mechanisms involved in regulation of penile smooth 
muscle tone. NO stimulates sGC which catalyses formation of cGMP. Increased cGMP concentrations lead 
to activation of PKG. cGMP or PKG reduce intracellular Ca2+ concentrations by various mechanisms 
leading to relaxation. Noradrenaline (NA) on the other hand stimulates α1-adrenoceptors which leads to 
production of IP3 via PLC. Increased IP3 concentrations lead to contraction by increasing intracellular Ca2+ 
concentrations. PKG, cGMP-dependent protein kinase; ER, endoplasmic reticulum; MLCK, myosin light 
chain kinase; Na/Ca Exch, sodium calcium exchanger; NO, nitric oxide; NA, noradrenaline, PLC, 
phospholipase C;  sGC, soluble guanylate cyclase.  (+) denotes activation and (-) denotes inhibition. 
 
It is known that the concentration of intracellular Ca2+ is critical for the regulation 
of penile vascular and cavernosal smooth muscle tone. A change in the concentration 
may be achieved by controlling the movements of Ca2+ into and out of the smooth muscle 
cells or the endoplasmic reticulum (Berridge, 1993). An increase in intracellular Ca2+ 
results in an increase in the activity of myosin light chain kinase (MLCK) and in turn the 
intracellular content of phosphorylated myosin light chain, which allows the smooth 
muscle cell to contract effectively (Berridge, 1993). 
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1.1.4.2 Endothelium-dependent hyperpolarizing factor (EDHF) 
As discussed earlier, NO is widely accepted to be the major mediator of 
endothelium dependent relaxation in the corpus cavernosum and penile arteries. 
However, in penile arteries there is another mechanism which remains despite blockade 
of NO and prostaglandins (Angulo et al., 2003). The hyperpolarisation of the cell 
membrane has been found to result in the closure of voltage-gated calcium channels. This 
in turn results in a reduced entry of calcium into both the extra-cellular and intra-cellular 
compartments and relaxation of the smooth muscle. This process of relaxation is 
prevented by maxi-K (Kca) channel blockade (Spektor et al., 2002) or by not allowing 
hyperpolarisation with a high K+ concentration (Angulo et al., 2003). Many authors have 
attributed this activity to an unknown endothelium-dependent hyperpolarizing factor 
(EDHF). It has been reported that putative candidates for EDHF include derivatives of 
arachidonic acid, hydrogen peroxide, anadamide and C-type natriuretic peptide. More 
recently, it has also been demonstrated that endothelium-dependent relaxation is impaired 
in both human penile corpus cavernosum and penile resistance vessels from diabetic 
patients (Angulo et al., 2006). However, treatment with dobesilate was found to enhance 
endothelium-dependent relaxation of penile resistance arteries which is attributed to 
EDHF. In contrast,  it had no effect on endothelium-dependent relaxation of the corpus 
cavernosum (Angulo et al., 2003). In a diabetic rat model, the combination of a PDE-5 
inhibitor and dobesilate was found to significantly improve erectile function greater than 
each individual agent alone. These results suggest a role for both NO-cGMP and EDHF 
pathways in erectile function (Angulo et al., 2005). 
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1.1.4.3 Vasoactive intestinal peptide (VIP) 
 
It has been reported that the penis has a rich supply of nerves containing VIP 
which are commonly co-localised with nNOS (Domoto and Tsumori, 1994;Ehmke et al., 
1995). The effects of VIP are mediated via two VIP receptors (types 1 and 2). 
Stimulation of the receptors results in an increase in cAMP and activation of cAMP-
dependent kinase activity (Miller et al., 1995). Experimental studies suggest that VIP has 
a role in NANC-mediated corpus cavernosal relaxation but its effect is dependent on the 
presence of prostaglandins and the generation of NO (Kim et al., 1995). Furthermore, it 
has been demonstrated that diabetes mellitus is associated with a reduction in the VIP 
immunoreactivity in nerves associated with cavernosal smooth muscle (Crowe et al., 
1983). 
 
1.1.4.4 Prostaglandins 
 
The corpus cavernosum has the ability to produce a wide variety of prostaglandins 
depending on the local oxygen tension (Andersson and Wagner, 1995;Daley et al., 1996). 
There at least five active prostaglandin metabolites that have been identified in penile 
tissues which may act on five major groups of receptors (Andersson and Wagner, 1995). 
The receptors in turn have been demonstrated to be G-protein coupled and are associated 
with different second messenger systems (Coleman et al., 1994). The precise role of the 
prostaglandins and their receptors in the penis has not yet been fully established. 
However, PGE1 and PGE2 may be involved in relaxation of smooth muscle via 
stimulating EP receptors whereas PGF2 and TXA2 are likely to result in contraction by 
stimulating TP and FP receptors respectively (Angulo et al., 2002;Hedlund et al., 1989). 
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1.1.5 Contractile factors 
It is generally accepted that the most important determinant of the whether the 
penis is in a state of tumescence or detumescence is the  degree of contraction of the 
corpus cavernosum smooth muscle (Andersson and Wagner, 1995). The activation of the 
sympathetic nervous system has consistently been demonstrated to result in the inhibition 
of erection. Furthermore, the tonic inhibitory activity of these nerves has been reported to 
result in the penis being kept in a flaccid state under normal circumstances (Andersson, 
2001b). There are many putative transmitters that may contribute to penile smooth 
muscle contraction, however noradrenaline and endothelins are currently believed to be 
the most important (Mills et al., 2001).  
 
1.1.5.1 Noradrenaline 
The penile vasculature and smooth muscle has been demonstrated to receive a 
dense adrenergic innervation. Noradrenaline acts upon α1-adrenoceptors, which are 
located on the smooth muscle cells of the corpus cavernosum, spongiosum and penile 
blood vessels (Andersson and Wagner, 1995). The post-receptor mechanisms after 
activation of adrenergic receptors include the release of membrane-bound phospholipase 
C, which induces cleavage of phosphoinositol diphosphate (PIP2) to inositol triphosphate 
(IP3) and diacylglycerol (DAG) (Figure 7). Both IP3 and DAG result in an increase in 
intracellular Ca2+, which in turn activates contractile pathways as described previously 
(Figure 6) (Berridge, 1993).  
 
However in vitro experiments have demonstrated that α adrenoceptor agonists 
induce a higher force/Ca2+ ratio than a direct depolarization-induced increase in 
intracellular Ca2+ (i.e. potassium chloride). These results suggest that there may in 
addition be a Ca2+-sensitizing effect associated with these agonists. One mechanism by 
which this may occur is through guanosine triphosphate (GTP)- binding proteins 
recruiting other messenger systems (Karaki et al., 1997;Kuriyama et al., 1998;Somlyo 
and Somlyo, 2000). 
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Figure 7: The mechanisms by which activation of adrenoceptors results in smooth muscle contraction via 
calcium dependent and independent mechanisms. Activation of myosin light-chain kinase (MLCK) by Ca2+ 
binding to calmodulin (CaM) leads to phosphorylation of myosin. Whereas, phosphokinase C (PKC) 
through phosphorylation of CPI-17 results in direct inhibition of myosin phosphatase. The ratio of kinase to 
phosphatase activities determines the level of phosphorylation and the extent of activation of myosin.  
 
In addition, other vasoactive mediators released from sinusoidal structures, such 
as angiotensin-II (Comiter et al., 1997), and thromboxane-A2 (Angulo et al., 2006), 
which possess smooth muscle contractile properties, can also interfere with smooth 
muscle relaxation and prevent erection.  However, their roles have not yet been fully 
established (Andersson and Wagner, 1995). 
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1.1.5.2 Endothelins 
Endothelin-1 (ET-1) is synthesised by the lacunar endothelium and has been 
reported to potently induce slowly developing, long-lasting contractions in the corpus 
cavernosum and penile vasculature. This may contribute to the maintenance of corpus 
cavernosal smooth muscle tone (Becker et al., 2001a). Smooth muscle contraction has 
also been reported to be produced by ET-2 and ET-3, although with a lower potency than 
ET-1 (Saenz, I et al., 1991a).  
 
Two ET receptors have been identified (A and B). Whilst ET-B is the most 
predominant in mammalians, it is ET-A which mediates the vasoconstrictor actions in the 
penis (Mumtaz et al., 2006). The contractions induced by ET-1 are dependent on trans-
membrane calcium flux (through voltage dependent and/or receptor operated calcium 
channels) and mobilization of IP3-sensitive intracellular calcium stores and calcium 
sensitization of the contractile machinery (Holmquist et al., 1990;Holmquist et al., 1992).  
Pathological states such as hypoxia have been found to be associated with an increase in 
the expression of ET-B receptors. This is a putative mechanism by which blood flow is 
increased secondary to smooth muscle relaxation (Filippi et al., 2003b;Mumtaz et al., 
2006). 
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1.1.5.3 Calcium sensitising pathways 
As described previously, the critical step in smooth muscle contraction is an 
increase in the intra-cellular free calcium [(Ca2+)i]. The increase in Ca2+ is transient 
whereas the vasoconstrictor induced smooth muscle constriction may be prolonged. One 
way that this may be accomplished is by increasing calcium sensitivity such that smooth 
muscle contraction prevails despite the return of Ca2+ to near basal levels (Somlyo and 
Somlyo, 2003).  
Calcium sensitization may be initiated by agonist activation of hetero-trimeric G 
protein coupled receptors. This activation results in the exchange of GTP for GDP on the 
small GTPase RhoA, and its dissociation from its partner Rho-guanine nucleotide 
dissociation inhibitor. GTP RhoA is then hypothesized to activate Rho kinase and inhibit 
MLC phosphatase, thus increasing MLC phosphorylation by basal level activity of MLC 
kinase. Using this pathway, the myosin phosphorylation and smooth muscle contraction 
may occur without a change in the concentration of Ca2+ from the sarcoplasmic (Figure 
8). 
 
Figure 8: Rho/Rho-kinase pathway.  
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Pathological states may abnormally increase the activation of myosin by Rho-
kinase using this mechanism. There is evidence that this may be the case in certain types 
of ED (Somlyo and Somlyo, 2000). Rees et al demonstrated by immunofluorescence and 
Western blotting the presence of Rho kinase in the primary culture of smooth muscle 
cells from human and rabbit corpus cavernosum (Rees et al., 2002). The same group also 
showed that a Rho-kinase inhibitor (Y-27632) relaxes human and rabbit cavernosal 
smooth muscle in an NO-independent manner (Rees et al., 2001). These results were 
further confirmed where Y-27632 caused a significant increase in corpus cavernosal 
pressure and erection independent of NO, without affecting systemic arterial pressure in 
rats (Chitaley and Webb, 2001).  
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1.2. Erectile dysfunction 
 Erectile dysfunction (ED) is defined as the inability to achieve and maintain a 
penile erection adequate for satisfactory sexual intercourse (1993).  It effects up to 150 
million men worldwide and this figure is projected to double by the year 2025 (Ayta et 
al., 1999).  
Many studies have attempted to characterise the true prevalence of ED. In a 
Danish study Ventegodt reported that 5.4% of all patients had a decreased ability to 
achieve an erection (Ventegodt, 1998). The prevalence was reported to be highest (18%) 
in those aged greater than 58 years.  
More recently, a Dutch study reported 13% of men had difficulties getting an 
erection and the prevalence increased with age. In the age groups of  40–49, 50–59, 60–
69 and 70–79 years, the incidence was found to be 6, 9, 22 and 38% respectively 
(Meuleman et al., 2001). 
The Massachusetts Male Aging Study (MMAS) is the most well known study to 
assess the prevalence of ED (Feldman et al., 1994). This study reported the results of a 
regional survey of 1709 men aged 40–69 years. Of the 1709 men surveyed, 1290 men 
completed a paper questionnaire. Of these men 52% reported ED, with 10% having 
complete ED. Moreover, the results suggest that the probability of complete ED at age 70 
was threefold that at age 40, the probability of moderate ED was two-fold, while that of 
minimal ED remained constant across all age groups. While the MMAS is regarded as 
representative of the population in Massachusetts, it has been criticised for its validity in 
terms of sociocultural diversity as 96% of the study population were Caucasian in origin. 
  In summary, studies of the prevalence of ED most commonly suggest that the 
incidence of ED increases sharply with age (Feldman et al., 1994). Furthermore, ED is a 
common cross-cultural condition, affecting 19% to 67% of men aged 40 to 80 years, in 
both developing and industrialized countries. 
However, it is now well understood that epidemiological studies may 
underestimate the true incidence of ED because of the perceived embarrassment that is 
associated with the condition (Chun and Carson, III, 2001). In an Australian study 
conducted in primary care, questionnaires were distributed to consecutive adult male 
attendees at 62 general medical practices. Of the 1240 completed questionnaires 39.4% of 
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men reported ED, however only 11.6% of these men had sought treatment for the disease 
(Chew et al., 2000).  
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1.3. Pathophysiology of erectile dysfunction 
 
ED can be caused by either psychogenic or organic causes, however in many 
patients the disorder is of mixed aetiology with both factors present. The psychogenic 
component of ED is reported to be especially important in younger men (aged less than 
35 years) (Melman and Gingell, 1999) and in elderly men who start a relationship with a 
new partner. Diseases which become more prevalent with age such as diabetes and 
vascular disease, are now known to be an integral in the pathogenesis of ED in the ageing 
male. It has been reported that in patients older than 50, up to 50% of these patients may 
have ED secondary to vascular disease (Kaiser, 1999). The presence of ED of any cause 
is itself associated with psychological distress. This of course may in turn reduce the 
probability of achieving satisfactory erectile function (Feldman et al., 1994). 
 
ED occurs when the normal function of one or more of the neuronal or muscular 
systems is interrupted and this is discussed below.  
 
1.3.1 Central nervous system 
The number of oxytocinergic neurons in the rat PVN and supraoptic nucleus 
decreases substantially with aging (Bazhanova et al., 1998). This age-related decrease 
may impair sexual function, since penile oxytocinergic neurons are postulated to have an 
important role in erection and ejaculation (Andersson and Wagner, 1995). 
The selective neuronal loss in the brain has been proposed to be related to an 
increase in the rate of programmed cell death by oxidative and nitrosative stress in these 
neurons (Torreilles et al., 1999). Peroxynitrite (produced by the reaction between NO and 
superoxide) is a strong oxidizing and nitrating agent. Increased levels of peroxynitrite 
have been demonstrated to occur with ageing. In the rat hypothalamic MPOA, the 
increased levels are postulated to be secondary to inducible nitric oxide synthase (iNOS) 
(Vernet et al., 1998). Moreover, an age-related increase in iNOS expression in the 
hypothalamus of the male rat has been observed. This region is involved in the control, 
the synthesis and neuronal secretion of Gn-RH and oxytocin and other factors which 
regulate penile erection (Ferrini et al., 2001). It is therefore possible that iNOS may have 
a pathological role in the reduction of Gn-RH and oxytocin. This in turn may result in 
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sexual dysfunction, which may manifest itself as a lowered serum testosterone level and 
reduced erectile function in ageing males. 
 
1.3.2 Spinal cord 
In spinal cord injury, patients with lesions above the sacral parasympathetic centre 
tend to have maintenance of reflex erections. These patients usually have short lasting 
erections which can be induced with minimal stimulation. This in contrast to lesions 
below the sacral centre, where there are no reflex erections and subsequently severe ED 
(Yarkony, 1990). 
 
1.3.3 Peripheral nervous system 
ED may occur when there is disruption to the afferent nerves which bring sensory 
information to the CNS or when there is a lesion in the autonomic nerves mediating 
arterial and trabecular smooth muscle relaxation. This may result secondary to conditions 
such as alcoholism, chronic renal failure and in cases of viral infections (e.g. HIV). 
 
1.3.4 Vascular disease 
Arterial disease can result in ED by restricting the inflow of blood into the penis. 
The most common cause of this is atherosclerosis. Furthermore, ED and cardiovascular 
disease share many common risk factors such as diabetes mellitus, hypertension, 
hypercholesterolemia and smoking. This has led to the hypothesis that ED may be an 
early manifestation of vascular disease i.e. endothelial dysfunction (Sullivan et al., 1999).  
The mechanisms involved in producing ED in vascular disease are complex and include 
arterial re-modelling (Saenz, I et al., 1991b), increased vasoconstriction (Schubert and 
Mulvany, 1999) and impaired neurogenic and endothelium dependent vasodilatation 
(Simonsen et al., 2002). 
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1.3.5 Diabetes mellitus 
Many epidemiologic studies have reported an increased risk of ED in diabetic 
men (Aytac et al., 2000). The prevalence of ED has been reported to affect between 35-
50% of diabetic patients (Akkus et al., 2002;Kolodny et al., 1974;McCulloch et al., 
1980). In an Italian study the authors reported that ED was more common in type 1 than 
type 2 diabetics. Furthermore, a positive relationship was demonstrated between ED, 
poor metabolic control and age (Fedele et al., 2001). These results indicate that diabetes 
is a very significant risk factor for the development of ED. 
In diabetes, the severity of ED has been demonstrated to be related to both the 
severity (Metro and Broderick, 1999), and duration of diabetes (McCulloch et al., 1980). 
However, it is likely that the aetiology of ED in diabetes is multifactorial. It is now well 
established that there is a higher incidence of peripheral neuropathy (Kolodny et al., 
1974), autonomic neuropathy (Bruna and Navarro, 2005), microangiopathy (McCulloch 
et al., 1980) and arterial insufficiency (Metro and Broderick, 1999) in diabetic patients 
with ED than in potent diabetic patients.  
 
The proposed mechanisms of ED in diabetic patients will now be discussed. 
  
a. Nitric oxide 
Studies have shown a reduction in eNOS- and nNOS- mediated cavernosal 
smooth muscle relaxation in diabetic animals (Azadzoi and Saenz, I, 1992;Cartledge et 
al., 2001b). Using immunhistochemistry, it was demonstrated in streptozotocin (STZ)-
induced diabetic rats, that nitrergic nerves undergo selective degeneration whereas anti-
erectile noradrenergic nerves remain intact. As a result, the nitrergic relaxation responses 
in vitro and erectile responses to cavernous nerve stimulation in vivo were found to be 
attenuated in diabetic animals, whereas the noradrenergic responses were enhanced 
(Cellek et al., 1999). 
In a rat model of type I (BB/WORdp diabetic prone) and type II (BBZ/WOR) 
diabetes, the amount of the nNOS protein has been shown to be reduced in diabetic rats 
(Vernet et al., 1995). Moreover, both diabetic models showed marked decreases of penile 
NOS activity and penile nNOS content compared to non-diabetic controls. By 
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administering an inhibitor of NO synthase, (L-NAME), to the drinking water of rats 
following the establishment of diabetes with STZ, it was demonstrated that L-NAME is 
able to protect the nitrergic nerves from morphological and functional impairment. These 
results suggest that selective nitrergic degeneration in diabetes is NO-dependent and that 
inhibition of NO synthase may be neuroprotective in this condition (Cellek et al., 1999).  
In vitro studies using corpus cavernosum from patients undergoing implantation 
of a penile prosthesis demonstrated that EFS-induced relaxation was less pronounced in 
the smooth muscle from diabetic men than in the smooth muscle from non-diabetic men. 
Furthermore, the degree of impairment was found to increase with the duration of 
diabetes(Saenz, I et al., 1989). Moreover, it has been found that NOS -containing 
(nitrergic) neurons innervating the penis of streptozotocin-induced diabetic rats undergo a 
selective degenerative process in two phases. In the first phase, nitrergic nerve fibres 
have been demonstrated to partially lose their NOS content and function, whereas in the 
second phase, nitrergic degeneration is considered to take place in the cell bodies in the 
ganglia. This results in an eventual complete loss of nitrergic function and nNOS content. 
Not surprisingly the changes in the first phase were found to be reversible with insulin 
replacement but the neurodegeneration in the second phase was not (Cellek et al., 2003). 
Thus these findings are in keeping with previous observations that the degree of erectile 
impairment increases with the duration of diabetes. These were further confirmed in 
human penile tissue from patients with diabetic ED (Tuncayengin et al., 2003).  
Other authors have suggested that the diabetes induced reduction in cavernosal 
NO could be due to a lack of essential co-factors for NOS enzyme (Escrig et al., 2002). It 
is also hypothesized that diabetes may impair the activity of guanylate cyclase, thereby 
decreasing the production of cGMP (Seftel et al., 1997). Thus decreased NO and its 
effector molecule, cGMP, may participate significantly in the development of diabetes 
induced ED. 
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b. Advanced glycation end products (AGEs) and superoxide production 
 
AGEs are thought to develop in diabetic patients secondary to hyperglycaemia 
and are the products of non-enzymatic reactions between glucose and lipids, proteins or 
nucleic acids (Cartledge et al., 2001a). It is now known that glucose reacts with the amino 
group of amino acids, resulting in the production of Schiff bases. These bases undergo a 
reversible reaction to form more stable Amadori products, however some of these 
glycosylation products undergo further chemical modifications and ultimately become 
irreversible glycosylation end-products, termed AGEs (Brownlee et al., 1988;Cartledge et 
al., 2001a). AGEs are able to form covalent bonds with vascular collagen, which may 
result in vascular thickening, reduced elasticity, endothelial dysfunction and 
atherosclerosis (Bucala et al., 1991);Singh, 2001 703 /id}. AGEs have also been found to 
accumulate in ageing and diabetic tissues, and may form at an accelerated rate when 
glucose levels are pathologically elevated (Bucala et al., 1991;Seftel et al., 1997). 
Furthermore, high-performance liquid chromatographic analysis has demonstrated a 
significant elevation of the AGEs in the penile tissue but not in the serum of diabetic 
patients compared with that of non-diabetic patients (Seftel et al., 1997). 
In vitro both haemoglobin (Hb) and HbA1c, an isoform of glycosylated 
haemoglobin have been found to significantly impair the relaxation of rat corpus 
cavernosum to acetylcholine in a dose-dependent manner. L-arginine addition has been 
found to reverse the impairment caused by Hb, but not glycosylated haemoglobin. The 
addition of pyrogallol (a donor of superoxide anions) resulted in a similar impairment in 
acetylcholine-induced relaxation in control tissues. However, the addition of SOD 
completely reversed the HbA1c-induced impaired relaxation. These results suggest that 
there is impaired endothelium-dependent smooth muscle relaxation in the corpus 
cavernosum from diabetic rats secondary to the presence of AGEs (Cartledge et al., 
2001a). Furthermore, AGEs have been shown to decrease compliance in the corpus 
cavernosum and interfere with smooth muscle relaxation by generating free radicals or 
reactive oxygen species (ROS) that react with NO (Cartledge et al., 2001a). Further 
studies demonstrate that a specific iNOS inhibitor (PNU- 1945 1) significantly 
potentiates the relaxation of pre-contracted human cavernosal tissue. These results 
suggest there may be a pathological mechanism for AGE-mediated ED via up-regulation 
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of iNOS and down regulation of eNOS (Seftel et al., 1997). ROS and superoxide anions 
have been shown to be elevated in diabetic rat penises. The product of the reaction 
between ROS and NO (peroxynitrite) does not itself elicit smooth muscle relaxation but 
may have a role in peroxide-induced cell damage and death (Cartledge et al., 2001a). 
AGEs can contribute to diabetic ED by generating oxygen free radicals, which induce 
oxidative cell damage and quench NO, culminating in decreased cGMP and impaired 
cavernosal smooth muscle relaxation (Bivalacqua et al., 2005;Cartledge et al., 
2001a;Khan et al., 2001).  
As discussed previously, in diabetes nitrergic neurones have been suggested to 
undergo a selective nitrergic degenerative process in two phases. More recent evidence 
suggests that AGEs increase the ROS and caspase-3-dependent neuronal apoptosis in a 
synergistic fashion with endogenous NO (Cellek et al., 2004). It has therefore been 
postulated that the apoptosis may be prevented with treatment by an NOS inhibitor, a 
pan-caspase inhibitor, a soluble receptor of AGEs s well as anti-oxidants. These results 
suggest that NO and AGEs act synergistically to produce irreversible nitrergic 
degeneration in diabetes. 
 
c. Endothelial dysfunction  
ED can be considered to be an early manifestation of systemic endothelial 
dysfunction (Billups, 2005). It is now well established that ED often precedes and 
predisposes subsequent atherosclerosis. Moreover, endothelial dysfunction is a reflection 
of the loss of NO activity or biosynthesis at the endothelial level. Despite this, the precise 
mechanisms involved in diabetes- associated endothelial dysfunction are incompletely 
understood. The known factors associated with endothelial dysfunction in diabetes 
include defects in endothelial NO synthase (eNOS) expression and activity; increased 
oxidative stress; decreased or impaired NO-independent relaxing factors; changes in the 
production or action of hormones, growth factors and cytokines; and the increased 
generation and activity of opposing vasoconstrictors (RhoA/Rho-kinase). The best-
characterized of these mechanisms are the result of hyperglycaemia. Elevated free fatty 
acids which are seen in patients with insulin resistance, may induce endothelial 
dysfunction through the activation of protein kinase C (PKC), the increased production of 
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reactive oxygen species (ROS), elevation in triglyceride and LDL, and decrease in HDL 
levels (Creager et al., 2003). More recent evidence suggests that the effects of 
hyperglycaemia and insulin resistance on endothelial cells are additive, since defects in 
both glucose and lipid metabolism produce similar effects with the resultant decrease in 
endothelial NO availability (Du et al., 2006;Du et al., 2003). The association between 
metabolic syndrome, insulin resistance and obesity and ED in men are now well 
characterised and understood (Esposito et al., 2005).  
 
d. ET-B receptor and ultrastructural changes  
ED in diabetic patients may be the result of an imbalance toward increased penile 
vasoconstriction possibly secondary to endothelin (ET) receptor signalling and 
ultrastructural changes in the endothelium. ET-1 produced by the vascular endothelium is 
a potent vasoconstrictor in the penis (Mills et al., 2001). ET-1 has been shown to be 
elevated in the plasma of diabetic patients (Takahashi et al., 1990). It has been 
hypothesized that ET-A receptors in cavernosal tissue have a vasoconstricting role. Thus, 
the elevation of the ET-A receptor and its ligand may cause the penile vasculature to have 
an imbalance toward vasoconstriction (Mumtaz et al., 2006). Furthermore, the ET-B 
receptor has been associated with pro-mitogenic effects which have been suggested to 
account for early ultrastructural changes of atherosclerotic-like lesions in diabetic patients 
(Khan et al., 2001;Sullivan et al., 1997). In a hypercholesterolemia rabbit model there 
was reported to be a reduction in the number of ETB receptors which may account for the 
reduced relaxation responses seen (Sullivan et al., 1998). Additionally, it has been shown 
that the tunica albuginea from diabetic rats is diminished and irregularly arranged. The 
structural alteration in the tunica albuginea is hypothesized to contribute to diabetic ED 
by impairing the veno-occlusive mechanism (Lu et al., 2004).  
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e. Rho kinase 
 As described previously, calcium sensitization may be initiated by agonist 
activation of hetero-trimeric G protein coupled receptors.  Abnormally increased 
activation of myosin by Rho-kinase using this mechanism may have a role in ED 
(Somlyo and Somlyo, 2000).  
In a diabetic rabbit model it  has been demonstrated that the corpus cavernosum 
exhibited increased sensitivity to ET-1 compared to controls (Chang et al., 2003). This 
increased sensitivity was associated with a 2-3 fold up-regulation of the ET-A receptor 
and could be blocked by the Rho-kinase inhibitor Y-27632. These results suggest that the 
increased ET-1-induced contraction is largely dependent upon Rho-kinase (Chang et al., 
2003).  This mechanism suggests a possible role involving the transduction pathways for 
the ET receptors in the pathogenesis of diabetic ED.  Moreover, Rho-kinase expression 
has now also been found to be increased in the diabetic vasculature and implicated in 
diabetes-induced nephropathy (Gojo et al., 2007;Xie et al., 2006). 
 
f. Cyclic GMP dependent kinase (PKG)  
It has been reported that the second messenger cGMP elicits cavernosal smooth 
muscle relaxation primarily through the action of  PKG (Lincoln and Cornwell, 1993). 
The PKG acts by altering intracellular calcium levels and opens calcium-dependent 
potassium channels leading to hyperpolarisation of smooth muscle cells(Chang et al., 
2004). Studies have demonstrated that PKG-1 knock-out mice have impaired cavernosal 
smooth muscle relaxation in response to neuronal and endothelial NO (Hedlund et al., 
2000a). Furthermore, in vitro studies have shown that both isoforms of PKG-1 (a and b) 
are able to protect cGMP from hydrolysis, with the a sub-type conferring a higher degree 
of protection (Kotera et al., 2003). Moreover, in diabetic rabbit corpus cavernosum, both 
isoforms of PKG-1 were found to be significantly reduced (PKG-1a was decreased more 
than PKG-1b) as well as a decrease in PKG-1 activity in the corpus cavernosum of 
diabetic rabbits as compared with normal rabbits (Chang et al., 2004). It is therefore 
possible that a decrease in both the quality and quantity in PKG-1 may be a mechanism 
by which to promote diabetic ED by reduced activity of the cGMP second messenger 
pathway.  
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1.4. Current pharmacological treatments for erectile dysfunction 
There are currently a broad range of options available for the management of ED. 
They include oral agents, intracavernosal injection (papaverine, phentolamine, 
prostaglandin E1, VIP), transurethral vasoactive agents (prostaglandin E1), vacuum 
erection devices, vascular surgery and penile prostheses. 
Oral agents are the least invasive option and are the most accepted form of 
treatment accepted by the majority of patients as a first line. In the following section, I 
present the current evidence for PDE5 inhibitors and briefly describe the role of other 
agents (Table 1). 
 
Oral Treatments Mechanism of action 
Sildenafil citrate (ViagraTM) PDE5 inhibitor 
Tadalafil (CialisTM) PDE5 inhibitor 
Vardenafil hydrochloride (LevitraTM) PDE5 inhibitor 
Phentolamine (VasomaxTM) α-adrenoceptor antagonist 
Doxazosin (CarduraTM) α-adrenoceptor antagonist 
Prazosin (MinipressTM) α-adrenoceptor antagonist 
Yohimbine α-adrenoceptor antagonist 
Terazosin (HytrinTM) α-adrenoceptor antagonist 
Trazodone (DesyrelTM) α-adrenoceptor antagonist 
Apomorphine  (UprimaTM, IxenseTM and 
TaluvianTM) 
Dopamine receptor agonist 
Table 1: The current oral agents for the treatment of male erectile dysfunction. 
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1.4.1 PDE5 inhibitors: 
The second messengers cGMP and cAMP are metabolized to GMP and AMP 
respectively by a superfamily of enzymes called phophodiesterases (PDEs) (Francis et 
al., 2001). Among all the PDEs PDE5, 6 and 9 are specific for cGMP and PDE5 is the 
predominant PDE in the corpus cavernosum (Francis et al., 2001;Michell et al., 1999).  
 
PDE5: cGMP-specific phosphodiesterase 
The physiological significance of PDE5 in the regulation of penile smooth muscle 
tone was confirmed by the first successful clinical use of a specific inhibitor of PDE5, 
sildenafil in the treatment of ED (Boolell et al., 1996). By inhibiting PDE5 hydrolytic 
activity sildenafil use has been found to be associated with a higher rate of accumulation 
of cGMP within the penile vasculature and cavernosal smooth muscle in response to NO. 
This increase in cGMP in turn enhances the erectile response (Ballard et al., 1998). Three 
different isoforms of PDE5 have been reported in human tissue, PDE5A1, A2 and A3 
(Lin et al., 2000).  In human corpus cavernosum PDE5A2 has been found to be the most 
abundantly expressed isoform (Lin et al., 2000).  
 
PDE5 inhibitors 
Sildenafil (ViagraTM), vardenafil (LevitraTM) and tadalafil (CialisTM) are the 
currently available PDE-5 inhibitors. Sildenafil and vardenafil differ only minimally in 
terms of their structure, while tadalafil differs markedly from both sildenafil and 
vardenafil in terms of its molecular structure. The PDE5 inhibitors have the same 
mechanism of action. However, they differ in their efficacy for the inhibition of the 
enzyme, in their selectivity for PDE5 over other isoenzymes such as PDE6 and in their 
pharmacological properties. 
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Potency and selectivity 
The potency of the PDE5 inhibitors can be measured in-vitro by assessing the 
IC50 value (concentration at which the enzyme activity is 50% inhibited) (Table 2). Using 
these values vardenafil exhibits a PDE5 inhibitory potential approximately five times 
higher than that of sildenafil (Kim et al., 2001). PDE6 plays an important role in the 
conversion of light impulses into nerve impulses in the retina. For PDE6 sildenafil and 
vardenafil show a lower selectivity than tadalafil. With respect to PDE11 tadalafil shows 
only 5 times greater selectivity with respect to PDE5 (Baxendale et al. 2001). PDE11 has 
been detected in a variety of human tissues, e.g. in the heart, pituitary gland, brain and 
testes. The physiological significance of PDE11 and the possible consequences of its 
inhibition have not yet been fully established.  
 
Pharmacokinetics 
All three drugs are rapidly absorbed from the gastrointestinal tract, with peak 
plasma levels being attained within 1 hour in the case of sildenafil (Milligan et al., 2002) 
and vardenafil (Rajagopalan et al., 2003) and after 2 hours in the case of tadalafil (Corbin 
and Francis, 2002). Food intake causes no delay or reduction in tadalafil absorption 
(Sussman, 2004), whereas it is known to reduce and delay sildenafil (Nichols et al., 
2002;Rajagopalan et al., 2003). The mean half-lives (t1/2) of sildenafil and vardenafil are 
3 - 4 hours whereas that of tadalafil is approximately 18 hours (Corbin and Francis, 2002) 
(Table 2). The elimination of sildenafil, vardenafil and tadalafil takes place 
overwhelmingly via the liver, mostly via the cytochrome enzyme P450 (CYP3A4) 
(Corbin and Francis, 2002). 
 
Clinical efficacy 
Results from clinical trials suggest that all three PDE-5 inhibitors are effective in 
a wide range of patient groups (Brock et al., 2002;Eardley et al., 2001;Hellstrom et al., 
2003). Treatment with vardenafil at a dose of 20 mg produced an improvement in the 
ability to achieve an erection in 80% of ED patients (Porst et al., 2001). In a comparable 
study of sildenafil (100 mg dose) by Goldstein, 84% of ED patients were successfully 
treated (Goldstein et al., 1998). Treatment with tadalafil 20 mg produced an improvement 
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in the ability to achieve an erection in 81% of ED patients (Padma-Nathan, 2003). More 
recently comparative studies between vardenafil and sildenafil suggest that patients do 
not have a significant preference between these two PDE5 inhibitors (vardenafil 38.9%; 
sildenafil 34.5%; and no preference 26.6%) (Rubio-Aurioles et al., 2006).  
 
Adverse effects 
The most common side effects seen with sildenafil include headache, flushing, dyspepsia, 
and rhinitis (Fagelman et al., 2001). The adverse effects with tadalafil and vardenafil are 
similar to sildenafil, however tadalafil is associated with a higher incidence of back pain 
(4-9%) and myalgia (1-7%). 
 
 Sildenafil Vardenafil Tadalafil 
Time to onset 30-60 min 25-40 min 45 min 
Duration of action 4-8 hours Up to 6 hours 24-36 hours 
IC50 for PDE5 (nM) 3.5-3.7 0.1-0.7 0.9-1.8 
*PDE1 80 500 >4450 
*PDE2 >8570 44290 >14800 
*PDE3 4630 >7140 >14800 
*PDE4 2190 43570 >14800 
*PDE5 1 1 1 
*PDE6 10 16 190 
*PDE7 6100 >214000 >14800 
*PDE8 8500 >214000 >14800 
*PDE9 750 4150 >14800 
*PDE10 2800 21200 >14800 
*PDE11 780 1160 5 
 
Table 2: Pharmacological properties of three PDE5 inhibitors sildenafil, tadalafil and vardenafil are shown 
as “time to onset” and “duration of action” obtained from clinical studies. IC50 values are from in vitro 
enzyme studies. * denotes the ratio of IC50 for that PDE enzyme over IC50 for PDE5 (Corbin and Francis, 
2002). 
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1.4.2 Alpha-adrenoceptor antagonists 
The sympathetic nervous system via stimulation of -adrenoceptors is considered 
to be the major determinant of cavernosal smooth muscle contraction and detumescence. 
Currently available antagonists include phentolamine, yohimbine, prazosin, doxazosin 
and terazosin. However none of these agents are commonly used for the treatment of ED 
due to poor efficacy and high incidence of adverse effects (Brock, 2000;Guay et al., 
2002;Kirby et al., 2005). 
 
1.4.3 Dopamine receptor agonists - apomorphine 
Apomorphine has been used in the treatment of a variety of medical conditions, 
including Parkinson’s disease. More recently, apomorphine has been shown to be 
effective in eliciting penile erection in both animal models and in humans (Lal, 1988). 
Apomorphine has been found to activate oxytocinergic neurons in the 
paraventricular nucleus (PVN) in the hypothalamus. This in turn projects to other key 
areas of the brain which regulate erectile function (Chen et al., 1999). Penile erection in 
rats, which increased in response to intraperitoneal injection of apomorphine, was 
reported to be inhibited by haloperidol, a central dopamine receptor antagonist but 
unaffected by domperidone, a peripheral dopamine antagonist (assi-Benelli et al., 1979). 
In rats, apomorphine was reported to directly activate the sacral pro-erectile nucleus. 
After stimulating the PVN, the sacral parasympathetic pro-erectile outflow may be 
activated, which results in a release of NO. There is then subsequent smooth muscle 
relaxation in the penis, corporal engorgement and erection (Giuliano et al., 2001). 
A sublingual route was used after it was discovered that subcutaneous 
formulations also stimulate an erectile response in men whilst minimizing side effects 
(Heaton et al., 1995). Sublingual apomorphine (UprimaTM, IxenseTM and TaluvianTM) is a 
centrally acting agent licensed for the treatment of ED in most European and South 
American countries, but not currently in the United States. 
Double-blind, placebo controlled crossover trials have shown that 2 and 3 mg of 
apomorphine were statistically superior to placebo in inducing an erection sufficient for 
intercourse in 38-53 % of patients depending on the underlying ED aetiology such as 
coronary artery disease, benign prostatic hypertrophy, hypertension and diabetes (Dula et 
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al., 2001;Dula et al., 2000). However, a recent post marketing observational cohort study 
of general practice prescribing for Uprima in the UK has reported a low level of 
effectiveness and a high incidence of discontinuation as a result of lack of efficacy 
(Maclennan et al., 2006). This is in keeping with the personal experience of most 
urologists and it is therefore now seldom prescribed. 
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1.5. Where do PDE5 inhibitors fail? 
PDE5 inhibitors prevent the hydrolysis of cGMP by PDE5, promoting its 
accumulation which ultimately augments penile smooth muscle relaxation. It is thought 
that a certain amount of NO is required for PDE5 inhibitors to be efficacious. Disease 
states which exhibit deficiencies in NO-cGMP pathway (due to decreased expression and 
activity of neuronal and endothelial nitric oxide synthases, impaired NO release or 
diminished NO bioavailability) will limit the efficacy of PDE5 inhibitors. If the 
pathophysiology is severe, PDE5 inhibitors will not be able to compensate the reduction 
in the NO-cGMP pathway. This will result in a failure of erectile dysfunction treatment. 
Highest rates of failure have been seen in long-term diabetes and after treatment for 
prostate cancer as summarised below: 
 
1.5.1 Diabetes mellitus 
Sildenafil 
The sildenafil Diabetes Study Group reported that 56% of men with ED and 
diabetes who received sildenafil (25-100mg) for 12 weeks reported improved erections 
(GAQ). This is contrast to placebo where only 10% reported better erections (Rendell et 
al., 1999). In a more recent double-blind, placebo-controlled, flexible-dose study patients 
were randomized to receive sildenafil (25-100 mg) or placebo for 12 weeks. The erectile 
function domain of the IIEF (See Appendix) showed only a 6-point increase in the mean 
score over placebo (Figure 9). However, men with mild/moderate ED achieved a higher 
overall score compared with men with severe ED (Rendell et al., 1999;Stuckey et al., 
2003). The percentage of improved erections (GEQ, 66.6 vs. 28.6%) and successful 
intercourse attempts (63 vs. 33%) was significantly higher with sildenafil compared with 
placebo. Moreover, similar responses were also reported in Type II diabetic patients 
(Boulton et al., 2001). In this study the majority of needed to take the maximum 
permitted dose in order to achieve an effect (100mg) (Kalinichenko et al., 1999). 
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Vardenafil 
In a multicentre double-blind placebo-controlled fixed-dose trial, patients with 
diabetes (type 1 or type 2) and ED were randomized to take 10 or 20 mg vardenafil or 
placebo as needed for 12 weeks. With respect to the erectile function domain, the dose-
dependent final scores for the 10- and 20-mg dose were 17.1 and 19.0 compared with 
12.6 for placebo (P < 0.0001). These two doses significantly enhanced the rates of 
successful penetration (P < 0.0001) and successful intercourse (P < 0.0001) compared 
with placebo. The results suggest that vardenafil was effective in increasing intercourse 
success rates irrespective of baseline ED severity, HbA1c level and for both type 1 and 2 
diabetes. However, the results did not show an improvement in erectile function domain 
to normal ranges (Goldstein et al., 2003). Similar results have been reported in a 
prospective, randomized study in PDE5 inhibitor-naive patients with type 1 diabetes. 
Vardenafil treatment significantly improved the erectile function domain score (P < 
0.0001) of the IIEF (From 13 to 20) (Ziegler et al., 2006) (Figure 9). These results are 
encouraging but are again inferior to results seen in other groups. 
 
Tadalafil 
In a study in both type 1 and type 2 diabetics, tadalafil was given at a dose of 10- 
20 mg taken up to once daily for 12 weeks. At doses of 10mg or 20mg, the erectile 
function domain score was improved by 6.4 and 7.3 respectively regardless of baseline 
HbA1c level (Saenz, I et al., 2002) (Figure 9). More recently a retrospective review of 
placebo-controlled trials reported that at baseline, patients with diabetes had more severe 
ED than patients without diabetes, with mean IIEF erectile function domain scores of 
12.6 and 15.0 respectively. In patients with diabetes receiving tadalafil at 20 mg, there 
was reported to be a mean improvement of 7.4 in their erectile function domain score 
against baseline versus 0.9 for placebo (p<0.001). Furthermore, the baseline erectile 
function domain scores were found to correlate inversely with baseline HbA1c levels. 
However, as for other PDE5 inhibitors, the response to tadalafil was lower in men with 
diabetes than in men without diabetes (Fonseca et al., 2004). 
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Figure 9: The change in erectile function (EF) domain of the IIEF in non-diabetic patients compared with 
diabetic patients after treatment with sildenafil 100mg (Carson et al., 2002;Stuckey et al., 2003), vardenafil 
20mg (Hellstrom et al., 2002;Ziegler et al., 2006) and tadalafil 20mg (Saenz, I et al., 2002;Seftel et al., 
2004).  
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1.5.2 Prostate cancer 
  An intact neurogenic innervation of the penis is required for physiological erectile 
responses. As a consequence patients with prostate cancer after either radical surgery or 
radiotherapy, have a high risk of post-operative ED. 
Sildenafil 
  In an open label study of sildenafil with ED after radical prostatectomy (RP), 53% 
of men receiving sildenafil (50-100mg) reported improved erections, whereas 40% 
reported an enhanced ability to achieve and maintain erections (Lowentritt et al., 1999). 
In this study the mean IIEF erectile function domain score increased from 9 to 14 (p 
<0.001) (Figure 10). Moreover, it was demonstrated that degree of ED was directly 
related to the degree of nerve sparing, a higher pathological stage and age. 
In a retrospective review of seven studies, the reported response rate to sildenafil 
was 14%-53% for an end point of erection sufficient for vaginal intercourse. This study 
also demonstrated evidence for a lower response rate after non-nerve-sparing (0%-15%) 
versus nerve-sparing surgery (35%-75%; but not after unilateral (10%-80%) versus 
bilateral nerve-sparing surgery (46%-72%). It was suggested that the odds of responding 
improved 12-fold with preservation of at least one neurovascular bundle (Feng et al., 
2000;Montorsi and McCullough, 2005).  
  The efficacy of sildenafil in patients with ED following radiation therapy for 
prostate cancer was assessed after three-dimensional conformal external beam irradiation 
or brachytherapy without androgen deprivation. Results were assessed at 3 time points. 
These were less than 12, 13-24 and 25-36 months following the completion of radiation 
therapy. The corresponding mean IIEF erectile function domain scores for these three 
time points after brachytherapy or external beam irradiation was 26/23, 22/19 and 17/15, 
respectively. Moreover, the percentage of patients who achieved normalization of the 
IIEF erectile function domain at the three time points in the brachytherapy or external 
beam irradiation groups was 60%/50%, 48%/42% and 26%/19%, respectively. The 
results of this study suggest that sildenafil can modestly improve erectile function 
following radiation therapy for prostate cancer. However, there appears to be a clear time 
dependence for the response to this therapy to be successful (Ohebshalom et al., 2005). 
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Moreover, sildenafil appears to improve erectile function to a greater degree following 
brachytherapy rather than external beam radiotherapy (Ohebshalom et al., 2005;Shemtov 
et al., 2004). 
Vardenafil  
In a double-blind study after bilateral nerve sparing retropubic radical 
prostatectomy, patients were randomized to take placebo or 10 or 20 mg of vardenafil. 
After 12 weeks both vardenafil doses were reported to be significantly superior to 
placebo (p <0.0001) for all efficacy variables assessed. The mean erectile function 
domain score improved from 9.2 to 15.3 after treatment with the higher dose of 
Vardenafil (Figure 10). When the average intercourse success rate per patient receiving 
20 mg vardenafil was assessed, it was reported that this variable was successful in 74% in 
men with mild to moderate ED and 28% in men with severe ED (compared to 49% and 
4% for placebo, respectively). The results of this study therefore suggest that vardenafil is 
able to significantly improve some of the key elements of erectile function in men with 
mild ED after nerve sparing RP but is less effective in cases of severe ED (Brock et al., 
2003;Ziegler et al., 2006). Similar results have now been reported in another randomized, 
placebo controlled, double-blind trial in the USA and Canada (Nehra et al., 2005). 
 
Tadalafil  
In a double-blind randomized controlled study involving men with ED after 
bilateral nerve sparing radical prostatectomy, patients were randomized to either tadalafil 
or placebo. Of the patients treated with tadalafil 62% reported improved erections at the 
completion of the study vs. 23% of controls. Furthermore, 54% of intercourse attempts 
were reported to be successful in penetrative intercourse compared to 32% of controls. 
However, the mean erectile function domain score showed only a small increase for 
patients receiving tadalafil (5.9) (Figure 10) (Montorsi et al., 2004). 
 
Following three-dimensional conformal external beam irradiation for prostatic 
carcinoma, the efficacy of tadalafil was assessed in a double-blind, placebo-controlled, 
cross-over study over a 12 week period. The patients received 20 mg of tadalafil or 
placebo for 6 weeks. There was reported to be a significant increase in the mean erectile 
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function domain score from baseline with tadalafil (8.4 to 17.7), but not with placebo 
(9.5). Furthermore, sixty-seven percent of the patients reported an improvement in their 
erectile function with tadalafil (placebo 20%), with 48% reporting the successful ability 
to have intercourse with tadalafil (placebo 9%) (p<0.0001) (Incrocci et al., 2006).  
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Figure 10: The changes in the erectile function (EF) domain of the IIEF in patients with no diabetes/radical 
prostatectomy after treatment with sildenafil (100mg) (Lowentritt et al., 1999), vardenafil (20mg) (Brock et 
al., 2003) and tadalafil (20mg) (Montorsi et al., 2004) versus post radical prostatectomy patients.  
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1.6 Soluble guanylate cyclase activators  
In the previous section ( see 1.5) I have discussed areas where PDE5 inhibitors 
fail. In order to achieve improved efficacy in these groups of patients, newer therapeutic 
strategies are required. One novel approach is to target the NO-independent activation of 
the enzyme sGC. The benzylindazole derivative, YC-1 is an activator of sGC (Friebe and 
Koesling, 1998). YC-1 has been shown to relax vascular (Wegener et al., 1997) and 
cavernosal (Mizusawa et al., 2002;Nakane et al., 2002) smooth muscle. YC-1 has also 
been shown to evoke erectile responses when given intracavernously and enhance 
erections induced by cavernous nerve stimulation and apomorphine when given 
systemically (Mizusawa et al., 2002). However it has been reported to have 
phosphodiesterase (PDE) inhibitory activity (Galle et al., 1999) and stimulate the 
synthesis and release of NO (Wohlfart et al., 1999).  
More recently, the pyrazolopyridine derivative BAY41-2272 (5- cyclopropyl-2-
[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b] pyridine-3-yl]pyrimidin-4ylamine) has been 
synthesized and shown to stimulate soluble guanylate cyclase in a NO-independent 
manner without an effect on cGMP breakdown (Becker et al., 2001b;Stasch et al., 2001). 
In contrast to YC-1, it has been shown to have a distinctly higher potency and no 
phosphodiesterase inhibitory activity (Stasch et al., 2001). However, it is not yet known 
whether NO-independent activation of sGC can lead to relaxation of cavernous smooth 
muscle.  
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1.7 Nitric oxide releasing PDE5 inhibitors  
A further potential approach to improving efficacy is the combination of a NO-
releasing compound with a PDE5 inhibitor. Recent evidence suggests that the PDE5 
inhibitor sildenafil has successfully been combined into a NO releasing formulation 
(sildenafil nitrate; NCX-911) (Figure 11).  
 
Figure 11: The structures of sildenafil and NCX-911 
 
It has been demonstrated that NCX-911 and sildenafil have similar selectivity and 
potency with respect to inhibiting PDE5 in-vitro (Riffaud JP, 2001).  
 65
NCX-911 has been previously shown to release NO spontaneously and increase 
cGMP concentrations by activating sGC and inhibit PDE5 (Seidler et al., 2002). 
Furthermore, NCX-911 has been shown to increase cGMP in a concentration dependent 
manner in the absence of endogenous NO. In comparison, it was found that sildenafil had 
little effect on cGMP concentrations under the same conditions (Riffaud JP, 2001). 
In a hypercholesterolemia rabbit model of erectile dysfunction, NCX-911 was 
shown to be significantly more potent (5-10 times) than sildenafil at reducing the 
phenylephrine-induced tone in the corpus cavernosum (Shukla et al., 2005). However it is 
not yet known whether NO-releasing PDE5 inhibitors have improved efficacy in 
conditions of NO deficiency.  
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1.8. Hypothesis and Aims of Thesis  
 Although the current therapeutic options for erectile dysfunction have been shown 
to be safe and efficacious, there clearly remains significant scope for further 
improvement. It is now well accepted that certain groups of patients, such as long-term 
diabetic patients and patients following treatment for prostate cancer respond less well to 
PDE5 inhibitors. Moreover, in these difficult to treat patient groups there does not appear 
to be any significant benefit for one PDE5 inhibitor over another. The reduced response 
to PDE5 inhibitors has been mainly attributed to a lack of NO bio-availability which may 
be in part due to a lack of endogenous NO production or availability. Therefore, new 
approaches which may potentially relax cavernosal smooth muscle without the need of 
endogenous NO are attractive. 
I therefore hypothesised that in conditions of NO deficiency in the corpus 
cavernosum and anococcygeus muscle, NO-independent sGC activators and NO-
releasing PDE-5 inhibitors may be more potent than PDE5 inhibitors at reducing smooth 
muscle tone and in potentiating nitrergic relaxations. 
The aim of my thesis was therefore to investigate in vitro effects of a PDE-5 
inhibitor (sildenafil), a NO-independent soluble guanylate cyclase activator (BAY 41-
2272) and an NO-releasing PDE5 inhibitor (NCX-911) on cavernosal (human and rabbit) 
and anococcygeal (rat) smooth muscle in conditions of NO deficiency. My further aim 
was to compare their efficacy with a non-selective sGC activator (YC-1) and a NO donor 
(spermine-NONOate).  
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CHAPTER 2. 
 
MATERIALS AND METHODS 
 68
2.0 Materials and Methods 
The hypothesis was tested in vitro using urogenital tissue obtained from male 
rabbits, rats and patients. All animal experiments were conducted according to the rules 
outlined by the Home Office, Animals (Scientific Procedures) Act 1986 (project number 
70/5161). The patients donating tissue to this study gave fully written informed consent 
and the study was approved by the Ethics Committee of the Riverside Health Authority 
and the Ethics Committees of the Mid Sussex National Health Service Hospital (RREC 
2911).  
2.1  In vitro experiments using rabbit corpus cavernosum 
Male New Zealand White rabbits weighing 3.0–3.5 kg (Harlan, UK) were housed 
in the Biological Services Unit, Wolfson Institute for Biomedical Research, University 
College London in conditions conforming to Home Office regulations. The rabbits were 
allowed to accommodate to their environment for at least one week before being used. 
The rabbits were killed with an intravenous overdose of phenobarbitone (200 mg/kg) 
(Euthesate, Willows Francis Veterinary, UK) injected into the marginal vein of the ear 
(Figure 12). 
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Figure 12:Phenobarbitone being injected into the marginal vein of a rabbit 
After confirmation of death, a lower midline incision was made above the 
symphysis pubis. The penile bulb was exposed by de-gloving the penis of overlying skin 
and fur. Once each crus was identified, care was taken to detach the penis as proximal as 
possible to its attachment to the pubic bone. The surrounding ischiocavernous and 
bulbospongiosus muscles were dissected off the penis and the whole organ placed in a 
container containing cold Krebs’ solution, which was continuously bubbled with 95% 
oxygen and 5% carbon dioxide. 
The penis was then pinned in a dish containing cold Krebs’ solution and the 
remaining overlying connective tissue and urethra were dissected free (Figure 13). A 
ventral corporotomy was made on each side of the penis and using fine dissecting 
instruments the erectile tissue was carefully dissected from the surrounding tunica 
albuginea (Figure 14). The corpus cavernosum was excised and cut longitudinally to 
obtain four identical strips (3 × 8 mm). Both ends of the cavernosal strips were ligated 
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using ties (which were used to mount strips) (Figure 15). The cavernosal strips were then 
mounted between ring electrodes in horizontal superfusion chambers. 
 71
?
Figure 13: The rabbit penis is placed in a dish containing Krebs’ solution. The specimen is held down 
gently with pins whilst the corpus cavernosum is dissected out. 
 
Figure 14: The overlying bulbospongiosus and connective tissue have been removed, exposing the ventral 
surface of the penis. A ventral corporotomy is made to help facilitate dissection of the corpus cavernosum.  
 
 
Corporeal Bodies 
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Figure 15: Each end of dissected rabbit corpus cavernosum is tied using 4-0 silk sutures. This then enables 
the strip to be easily mounted in a superfusion chamber. 
Cavernosal strip 
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2.2 In vitro experiments using human corpus cavernosum 
Whole corpus cavernosum was obtained from patients undergoing penectomy for 
gender reassignment at Charing Cross Hospital, London and Sussex Nuffield Hospital, 
Brighton, UK. Tissues were transported from hospital to the laboratory in ice-cold Krebs’ 
solution in less than 2 hours. After arrival they were transferred to Krebs’ solution at 
room temperature and cleaned of adherent tissue and blood. Eight strips (3 x 8mm) were 
cut from middle part of each corpus cavernosum. 
2.3 In vitro experiments using anococcygeus muscle from diabetic and non-diabetic 
rats 
Male Wistar rats (Harlan, UK) weighing 200–250 g were divided into two groups. 
Diabetes was induced in one group by a single intraperitoneal injection of streptozotocin 
(STZ; 75 mg/kg) as described previously (Cellek et al., 2003;Cellek et al., 1999). The 
other group was injected with the vehicle (saline). Sixteen weeks after STZ injection the 
animals were weighed and killed with cervical dislocation. Blood samples were collected 
for analysis of serum glucose levels (Reflolux S Glucometer, Boehringer Manheim, 
Germany) and bilateral anococcygeus muscles were isolated for functional studies as 
described previously (Cellek et al., 2003).  
An abdominal midline incision was made and the genital organs, bladder and 
urethra cleared, then the pelvis split. The exposed colon was cut at the pelvic brim and 
the pelvic portion pulled forward to reveal the two underlying muscles surrounded by 
connective tissue. A maximal length of each muscle was then carefully removed. Each 
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anococcygeus muscle was cleaned of adherent tissues and mounted horizontally between 
two ring electrodes in horizontal superfusion chambers. 
 
2.4 Horizontal superfusion chamber: 
Each preparation (human or rabbit corpus cavernosum or rat anococcygeus 
muscle) was mounted horizontally between two ring electrodes (4 mm diameter) in 
superfusion chambers (37°C) as described previously (Cellek and Moncada, 1997b) 
(Figures 16 and 17).  The chambers were perfused with Krebs' solution at a constant flow 
of 1.0 ml/min by means of peristaltic pumps (Miniplus 2, Gilson, United Kingdom). One 
end of the preparation was tied to a FT03C (Grass Instruments, Massachusetts, USA) 
force-displacement transducer connected to a Linearcorder WR 3101 (Graphtec, Tokyo, 
Japan) and a computer for registration of isometric changes in tension (Figure 17). A 
schematic diagram of the laboratory set- up is shown in Figure 18.  
The preparations were stretched until they reached approximately the in situ 
length (0.4–1 g in rabbit corpus cavernosum, 0.5 g in rat anococcygeus muscle, 0.6 g in 
human corpus cavernosum) and allowed to equilibrate for 90 min. The preparations were 
stimulated electrically for 5 s with trains of rectangular pulses of 50 V, 0.3 ms pulse 
duration and at a range of frequency of 0.5-25 Hz, delivered by Grass S88 stimulators. 
The recorder was run at a rate of 25 mm/min to record the mechanical responses. The 
mechanical responses were also recorded on a computer by a specialized data acquisition 
system (Axon Instruments, USA). The chemicals were applied directly to the reservoir 
holding the Krebs’ solution. 
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Figure 16: Each dissected strip of corpus cavernosum is mounted into a superfusion chamber.  
One end is attached to a transducer to detect changes in tension and the other end fixed. 
 
Cavernosal 
strip 
Transducer 
Double 
Jacketed 
superfusion 
chamber 
 76
 
 
 
 
 
 
 
 
 
Figure 17: Overview of the laboratory set up showing superfusion chambers, organ bath and tubing. 
 
 
Figure 18: Schematic illustration of the experimental set up 
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2.5 Krebs’ solution and chemicals 
Fresh Krebs’ solution was prepared each day of the following ionic composition 
(mM): NaCl 136.9, KCl 2.7, CaCl2 1.8, MgSO4 0.6, NaHCO3 11.9, KH2PO4 0.5, glucose 
11.5, indomethacin 0.01, dexamethasone 0.01. The solution was bubbled continuously 
with 95% oxygen and 5% CO2 and the pH of the solution was maintained at 
approximately 7.0-7.2.  
The inducible form of NOS (iNOS) can be induced by trace amounts of endotoxin 
in the buffer (Rees et al., 1990) and cause loss of tone (Cellek and Moncada, 1997a). 
Dexamethasone (0.01mM) was added to the Krebs’ solution to prevent induction of 
iNOS (Rees et al., 1990). The cyclooxygenase inhibitor indomethacin (0.01mM) was 
added to prevent synthesis of prostaglandins since these can cause non-neurogenic 
relaxations (Daniel et al., 1979).  
NCX-911 was a gift from NicOx, France. Sildenafil citrate was extracted from 
Viagra® tablets as the free base, analysed by 1H-NMR and LC/MS to confirm identity 
and purity (>97%) and then converted to its citrate salt by Dr. D. Madge at the Medicinal 
Chemistry Department, Wolfson Institute for Biomedical Research, University College 
London. Tetrodotoxin was obtained from Calbiochem, UK.  BAY41-2272 (5-
cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-
4ylamine) was a gift from Bayer AG, Germany.  All other chemicals were obtained from 
Sigma, UK. 
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2.6 Statistical analysis and presentation of the results 
 The effect of drugs on phenylephrine-induced contraction was expressed as a 
percentage reduction in tone. Results are expressed as mean ± standard error of the mean. 
Statistical analysis was performed using Student's unpaired two-tailed t-test. A 
probability value (P) less than 0.05 was considered to be statistically significant. The 
statistical analysis was performed using Graphpad Prism software (version 3.00, 
GraphPad Software Inc, San Diego, California, USA). n denotes either the number of 
patients or the number of animals. EC50 values were calculated using Microcal Origin 
software (Version 4.0, Microcal Software Inc, USA). 
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2.7 Experimental design 
2.71 Effect of compounds on elevated tone in the human and rabbit corpus 
cavernosum and rat anococcygeus muscle 
 
Strips of corpus cavernosum from the rabbit and human and anococcygeus muscle 
from rat were incubated in Krebs’ solution and allowed to equilibrate for 90 minutes. 
Electrical field stimulation (EFS) was applied to assess the viability of the tissue. 
Guanethidine (10M) and scopolamine (10M) were added to the organ bath to inhibit 
adrenergic and cholinergic responses respectively after which EFS was stopped. The 
EC80 for phenylephrine for each tissue (rabbit and human corpus cavernosum, rat 
anococcygeus) was then determined by constructing a concentration response curve with 
cumulative additions of the compound (10 nM-1 mM). The effects of BAY41-2272, YC-
1, spermine NO-NOate, sildenafil or NCX-911 were then investigated on the tone 
elevated by EC80 of phenylephrine in the absence or presence of an inhibitor of sGC, 
ODQ (30µM) or an inhibitor of NO synthase, L-NAME (500µM). 
?
2.72 Investigation of the effects of compounds on nitrergic relaxations 
Nitrergic relaxations were obtained using EFS in the rabbit and human corpus 
cavernosum and rat anococcygeus muscle after treatment with scopolamine and 
guanethidine and elevation of the tone by EC80 of phenylephrine. To study the effect of 
the compounds on nitrergic relaxations 2 sub-threshold concentrations (30 and 50 nM for 
BAY41-2272; 10 and 30 nM for sildenafil and NCX-911) were used (concentrations 
which do not reduce phenylephrine-induced tone) in the absence or presence of L-
 80
NAME. The effect on the duration and magnitude of relaxations was assessed by 
measuring the area under the curve of each relaxation before and after the compound.  
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CHAPTER 3. 
RESULTS 
 82
3.0 Results 
 
3.1 Determination of the EC80 for phenylephrine 
The EC80 for phenylephrine was determined by constructing concentration 
response curves with incremental cumulative additions of the compound (10-8 – 10-3 M) 
in the absence of electrical field stimulation (EFS) (n=8; Figure 19).  The calculated EC80 
was 3µM in both rabbit and human corpus cavernosum.  
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Figure 19: Concentration response curve to phenylephrine in strips of human corpus cavernosum.  EC80 for 
phenylephrine (3 µM) was then calculated using this curve. Each data point represents mean of 8 separate 
experiments, error bars represent the error of the mean. 
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3.2 Eliciting nonadrenergic noncholinergic relaxation responses to EFS in rabbit 
and human corpus cavernosum 
 
Electrical field stimulation (EFS; 50 V, 0.3ms pulse duration, 0.5-25Hz, for 5s, 
every 120 s) elicited reproducible contractions of both rabbit and human corpus 
cavernosum strips. These contractions were inhibited with guanethidine (10µM). Further 
addition of scopolamine (10µM) inhibited any cholinergic component of neuronal 
stimulation. In the presence of scopolamine and guanethidine, further addition of 
phenylephrine (3 µM) caused elevation of the tone. EFS under these conditions elicited 
reproducible nonadrenergic noncholinergic (NANC) relaxation responses (Figure 20). 
The optimum frequency (i.e. giving the greatest relaxation response) was found to be 5 
Hz for both tissues. These frequency-dependent relaxations were completely inhibited by 
an inhibitor of sGC (ODQ; 30 µM), an inhibitor of NO synthase (L-NAME, 500 µM; 
Figure 22) or tetrodotoxin (TTX, 1 µM; not shown) indicating that they were nitrergic in 
nature and neurogenic in origin. L-NAME also elevated the tone at 23.25% and 28.2% in 
human corpus cavernosum and in rabbit corpus cavernosum respectively (mean, n=8 for 
each). 
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Figure 20: Electrical field stimulation (EFS) (50 V, 0.3 ms pulse duration, 5 Hz, for 5 s, every 120 s, 
denoted with solid dots) was applied to rabbit corpus cavernosum. The addition of scopolamine and 
guanethidine (both at 10 µM) and phenylephrine (3 µM) resulted in elevation of the tone and the 
appearance of NANC relaxation responses. In this trace the baseline and the speed of the recorder were 
adjusted (as denoted with an arrow) to allow the full responses to be demonstrated on the trace.  
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Figure 21: EFS (50 V, 0.3ms pulse duration, 5Hz, for 5s, every 120 s, as denoted by solid dots) elicited 
contractions in rabbit corpus cavernosum. Addition of phenylephrine (3 µM), scopolamine (10 µM) and 
guanethidine (10 µM) abolished EFS-induced contractions and elevated the tone. Under these conditions 
same EFS elicited NANC relaxation responses which were abolished by L-NAME (500 µM). The addition 
of L-NAME also resulted in further elevation of the tone. On this trace please note that the sensitivity of the 
recorder was reduced by 50% and the baseline was adjusted (denoted by black arrow) and the speed of the 
recorder was reduced (denoted by red arrow) to allow demonstration of the full responses on the trace.  
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3.3 Investigation of the effect of sGC activators on rabbit and human corpus 
cavernosum  
3.31 Effect of BAY41-2272 on phenylephrine-induced tone  
The addition of cumulative concentrations of BAY41-2272 resulted in a 
concentration-dependent reduction of phenylephrine-induced tone in both rabbit 
(EC50=407.5±22.7 nM) and human (EC50=300.3±33.8 nM) cavernosal strips (n=12 for 
both) (Figure 22, Tables 3 and 4).  
10 100 1000 10000
0
20
40
60
80
100
 Human corpus cavernosum
 Rabbit corpus cavernosum
TO
NE
 (%
) o
f c
on
tro
l
Log Concentration BAY 41-2272 (nM)
 
Figure 22: The effect of BAY41-2272 in reducing the phenylephrine-induced tone in human (closed 
squares) and rabbit corpus cavernosum (open squares). Each data point represents mean of 12 separate 
experiments, error bars represent the error of the mean. 
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3.32 Investigation of the effect of BAY41-2272 on phenylephrine-induced tone in the 
presence and absence of ODQ 
 
The sGC inhibitor, ODQ (10 and 30 µM) caused a rightward parallel shift in the 
dose-response curve to BAY41-2272 in both the rabbit and human corporal tissues. In the 
presence of 30 µM ODQ, EC50 of BAY41-2272 was 1905.3±14.4 nM and 1407.3±158 
nM and in the rabbit and human tissues, respectively (n=8; Figures 23 and 24, Tables 3 
and 4).   
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Figure 23: The effect of BAY41-2272 in reducing the phenylephrine-induced tone in rabbit corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 30 µM ODQ (+ ODQ, open 
squares). Each data point represents mean of eight separate experiments, error bars represent the standard 
error of the mean. 
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Figure 24: The effect of BAY41-2272 in reducing the phenylephrine-induced tone in human corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 30 µM ODQ (+ ODQ, open 
squares). Each data point represents mean of eight separate experiments, error bars represent the standard 
error of the mean.  
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3.33 Effect of BAY41-2272 on phenylephrine-induced tone in the presence and 
absence of L-NAME 
 
The addition of the NO synthase inhibitor L-NAME at 500 µM resulted in a 
rightward parallel shift in the concentration response curve to BAY41-2272. In the 
presence of 500 µM L-NAME EC50 values of BAY41-2272 were 836.7±46.7 nM in the 
rabbit and 429.1±30.9 nM in human tissue (n=8; Figures 25 and 26, Tables 4 and 5). In 
both rabbit and human tissues these EC50 values were not significantly different from 
EC50 values obtained in the absence of L-NAME (p>0.05; Tables 3 and 4). 
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Figure 25: The effect of BAY41-2272 in reducing the phenylephrine-induced tone in rabbit corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares). Each data point represents mean of eight separate experiments, error bars represent the standard 
error of the mean. 
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Figure 26: The effect of BAY41-2272 in reducing the phenylephrine-induced tone in human corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares). Each data point represents mean of eight separate experiments, error bars represent the standard 
error of the mean. 
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3.34 Investigation of the effect of YC-1 on phenylephrine-induced tone in rabbit and 
human corpus cavernosum 
 
The administration of another sGC activator YC-1 resulted in a concentration-
dependent reduction of phenylephrine-induced tone in rabbit and human corpus 
cavernosum with EC50 values of 13173.2±2018.4 nM and 25335.9±3332.8 nM 
respectively (n=8; Figure 27).  
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Figure 27: The effect of YC-1 in reducing the phenylephrine-induced tone in human (closed squares) and 
rabbit corpus cavernosum (open squares). Each data point represents mean of eight separate experiments, 
error bars represent the standard error of the mean. 
 
Significantly higher concentrations of YC-1 were required to induce relaxation of 
phenylephrine-induced tone compared to BAY41-2272. In comparison to BAY41-2272 
there was a 32-120 fold difference in the potency with respect to the EC50 (p< 0.0001 vs. 
BAY41-2272) (Figure 28). 
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Figure 28: The effect of YC-1 in reducing the phenylephrine-induced tone in human corpus cavernosum 
(open squares) in comparison to BAY41-2272 (closed squares) (p>0.05). Each data point represents mean 
of eight separate experiments, error bars represent the standard error of the mean. 
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3.35 Investigation of the effects of spermine-NONOate on phenylephrine-induced 
tone in rabbit and human corpus cavernosum in the presence and absence of L-
NAME 
 
The addition of increasing concentration of the NO donor spermine-NONOate 
resulted in a concentration dependent relaxation of phenylephrine-induced tone with EC50 
values of 843.3±54.4 nM in rabbit (Figure 29) and 1220.54±19.3 nM in human corpus 
cavernosum (Figure 30). The addition of L-NAME at 500µM did not result in any 
significant change in the efficacy or potency of spermine-NONOate in rabbit tissues 
(EC50=698.42±61.9 nM P=0.1002) (Figure 29). The experiment with L-NAME was not 
repeated on human tissues because the results in rabbit tissues were easily reproducible 
and conclusive and the cost and availability of the NO donor spermine-NONOate was a 
significant limiting factor. Furthermore, there were no significant differences in the 
responses to spermine-NONOate between the rabbit and human tissues in the absence of 
L-NAME. 
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Figure 29: The effect of spermine-NONOate in reducing the phenylephrine-induced tone in rabbit corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares) (p>0.05). Each data point represents mean of eight separate experiments, error bars represent the 
standard error of the mean. 
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Figure 30: The effect of spermine-NONOate in reducing the phenylephrine-induced tone in human corpus 
cavernosum. Each data point represents mean of ten separate experiments, error bars represent the standard 
error of the mean. 
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3.36 Investigation of the effects of spermine-NONOate on phenylephrine-induced 
tone in rabbit corpus cavernosum in the presence and absence of ODQ 
 
In the presence of ODQ at 10 and 30 µM respectively, there was a concentration-
dependent significant right ward shift in the concentration-response curve in rabbit 
corpus cavernosum (Figure 31).  EC50 values for spermine-NONOate in the presence of 
10 µM and 30 µM ODQ were 6091.2±1718.6 nM and 41479.0±17711.2 nM respectively 
(both p<0.0001 vs. control).  
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Figure 31: The effect of spermine-NONOate in reducing the phenylephrine-induced tone in rabbit corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 10 µM ODQ (+ ODQ, open squares) 
(p<0.001)  and 30 µM  ODQ (+ ODQ, triangle) (p<0.001). Each data point represents mean of six separate 
experiments, error bars represent the standard error of the mean. 
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In comparison to spermine-NONOate, the potency of BAY41-2272 was at least 2 
fold greater in reducing phenylephrine-induced tone in both rabbit and human corpus 
cavernosum respectively (p<0.001; Tables 3 and 4, Figure 32). 
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Figure 32: The effect of BAY41-2272 (solid squares), YC-1 (open squares) and spermine-NONOate 
(triangles) in reducing the phenylephrine-induced tone in rabbit corpus cavernosum. Each data point 
represents mean of six separate experiments, error bars represent the standard error of the mean. 
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Rabbit EC50 mean ± s.e.m.(nM) N 
BAY41-2272 
 
407.5±22.7 12 
+ ODQ 30 µM 1905.3±14.4* 
 
8 
+ L-NAME 500 µM 836.7±46.7 
 
8 
YC-1 13173.2±2018.4** 
 
8 
Spermine-NONOate 843.3±54.4 
 
6 
+ODQ 30 µM 41479±17711.2*** 
 
6 
+ L-NAME 500 µM 698.4±61.9 
 
8 
 
Table 3: The EC50 values of BAY41-2272, YC-1 and spermine-NONOate for lowering phenylephrine 
induced tone in rabbit corpus cavernosum in the absence or presence of ODQ or L-NAME. n denotes the 
number of animals used for each set of experiments. *P<0.05 vs. BAY 41-2272 in the absence of L-NAME 
or ODQ, ** P<0.05 vs. BAY 41-2272, *** P<0.05 vs. spermine-NONOate in the absence of L-NAME or 
ODQ. 
 
Human EC50 mean ± s.e.m.(nM) 
 
N 
BAY41-2272 
 
300.3±33.8 12 
+ODQ 30 µM 
 
1407.3±158.0* 8 
+ L-NAME 500 µM 
 
429.1±30.9 8 
YC-1 
 
25335.9±3332.8** 8 
Spermine-NONOate 
 
1220.5±19.27*** 6 
 
Table 4: The EC50 values of BAY41-2272, YC-1 and spermine-NONOate for lowering phenylephrine 
induced tone in human corpus cavernosum in the absence or presence of ODQ or L-NAME. n denotes 
number of patients used for each set of experiments. *P<0.05 vs. BAY 41-2272 in the absence of ODQ, ** 
P<0.05 vs. BAY 41-2272, *** P<0.05 vs. BAY 41-2272. 
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3.4 Investigation of the effects of BAY41-2272 on nitrergic relaxations 
 
My preliminary experiments have demonstrated that BAY41-2272 was able to 
reduce the phenylephrine-induced tone at concentrations greater than 50 nM. At 
concentrations greater than 50 nM it was therefore not possible to evaluate the EFS-
induced relaxation responses since reduction in the tone would alter the magnitude of the 
neurogenic relaxation responses. Therefore, two concentrations (30 and 50 nM) were 
chosen to study the effect of BAY41-2272 on nitrergic relaxation responses. At these 
sub-threshold concentrations BAY41-2272 potentiated both the duration and magnitude 
of the relaxation responses especially at low frequencies without significantly altering the 
tone (n=4) (Figure 33).  
I also investigated whether BAY41-2272 would restore nitrergic relaxation 
responses after they were inhibited with an inhibitor NO synthase. In order to achieve 
this, firstly I blocked the nitrergic relaxations using L-NAME (500 µM). Administration 
of BAY41-2272 after complete inhibition of nitrergic responses caused a reduction in the 
phenylephrine-induced tone. Concentrations above 0.3 µM of BAY41-2272 caused 
partial restoration of the nitrergic responses even at reduced tone such that 12.3±3.6% of 
nitrergic responses were recovered after addition of 3 µM BAY41-2272 (n=4) (Figure 
34). 
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Figure 33: Electrical field stimulation (EFS; 50 V, 0.3 ms pulse duration for 5 seconds at 0.5 to 10 Hz) 
elicited nitrergic relaxations in rabbit corpus cavernosal strips (n=4). A, relaxations were enhanced in 
magnitude and duration by 30 and 50 nM BAY41-2272. Values above circles indicate stimulation 
frequencies. B, area under curve (AUC) of each EFS-induced relaxation was measured and expressed as 
percent of relaxation induced at 0.5 Hz under control conditions in same tissues. 
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Figure 34: Electrical field stimulation (circles) at 50 V with 0.3 ms pulse duration for 5 seconds at 5 Hz 
elicited nitrergic relaxations in rabbit corpus cavernosal strips (n=4). 500 µM L-NAME abolished these 
relaxations. Under these conditions treatment with (0.3 to 3 µM BAY41-2272) reduced the tone and 
partially restored inhibited relaxations. 
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3.5 Investigation of the effect of sildenafil on rabbit and human corpus cavernosum 
 
Increasing cumulative concentrations of sildenafil (1 nM – 300 µM) were added 
to construct the concentration-response curves. Sildenafil caused reduction of 
phenylephrine-induced tone in both rabbit and human cavernosal strips in a 
concentration-dependent manner with a similar potency. EC50 values for rabbit and 
human corpus cavernosal tissues were 1000.5±140.8 nM and 800.7±155.8 nM (n=10 for 
both) respectively (Figure 35 and Tables 5 and 6). 
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Figure 35: The effect of sildenafil in reducing the phenylephrine-induced tone in human (solid squares) 
(EC50=800.7±155.8 nM) and rabbit corpus cavernosum (open squares) (EC50=1000.5±140.8 nM). Each 
data point represents mean of ten separate experiments, error bars represent the standard error of the mean. 
Please note that the two curves were identically overlaid on each other. 
?
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3.51 Investigation of the effect of sildenafil on phenylephrine-induced tone in the 
presence of L-NAME 
 
The addition of L-NAME (500µM) resulted in a significant rightward parallel 
shift in the concentration response curve to sildenafil. The EC50 of sildenafil was 
4959.1±882.1 nM in rabbit (n=8, P<0.05 vs. control) and 2446.7±256.8 nM in human 
tissues (n=6, P<0.05 vs. control) in the presence of 500 µM L-NAME (Figures 36 and 37, 
Tables 5 and 6). 
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Figure 36: The effect of sildenafil in reducing the phenylephrine-induced tone in rabbit corpus cavernosum 
in the absence (CONTROL, solid squares) or presence of 500 µM L-NAME (+L-NAME, open squares). 
Each data point represents mean of eight separate experiments, error bars represent the standard error of the 
mean. 
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Figure 37: The effect of sildenafil in reducing the phenylephrine-induced tone in human corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares). Each data point represents mean of six separate experiments, error bars represent the standard 
error of the mean. 
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3.52 The effect of sildenafil on phenylephrine-induced tone in human corpus 
cavernosum in the presence and absence of ODQ 
 
 
Once the tone was established, increasing concentrations of sildenafil 
(1 nM−300 µM) were added to construct the concentration–response curves in the 
absence or presence of an inhibitor of soluble guanylate cyclase, ODQ (10 µM) (Figure 
38). 
In the presence of 10 µM ODQ, sildenafil failed to induce a significant relaxation 
below 1 µM. Even above 1 µM, sildenafil could only reach 50% of the tone resulting in 
a significant rightward and upward shift in the concentration–response curve. The EC50 
value for sildenafil in the presence of ODQ was 6488.0±938.0 nM (n=6) (Figure 38 and 
Table 6). 
?
?
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Figure 38: The effect of sildenafil in reducing the phenylephrine-induced tone in human corpus 
cavernosum in the absence (control, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares) or 10 µM ODQ (+ODQ, triangles). 
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3.53 Investigation of the effect of NCX-911 on phenylephrine-induced tone in rabbit 
and human corpus cavernosum 
 
Administration of increasing concentrations of NCX-911 resulted in relaxation of 
rabbit and human cavernosal strips in a concentration-dependent manner (n=8 for both, 
EC50=997.8±195.7 nM and 733.1±94.4 nM in rabbit and human respectively) (Figure 39 
and Tables 5 and 6).  
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Figure 39: The effect of NCX-911 in reducing the phenylephrine-induced tone in human (solid squares) 
and rabbit corpus cavernosum (open squares). Each data point represents mean of eight separate 
experiments, error bars represent the standard error of the mean. 
?
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3.54 The effect of NCX-911 on phenylephrine-induced tone in rabbit and human 
corpus cavernosum in the presence and absence of L-NAME 
 
The NO synthase inhibitor L-NAME resulted in a slight rightward parallel shift in 
the concentration response curve to NCX-11. In the presence of 500 µM L-NAME, EC50 
values of NCX-911 were 1281.2±268.3 nM (n=8, p=0.41 vs. control) and 980.4±106.7 
nM (n=8, p=0.1132 vs. control) in rabbit and human tissue respectively (Figures 40 and 
41, Tables 5 and 6). Even when the concentration of L-NAME was increased to 1 mM 
there was no significant effect in rabbit cavernosal tissues (p=0.72; not shown). 
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Figure 40: The effect of NCX-911 in reducing the phenylephrine-induced tone in rabbit corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares). Each data point represents mean of eight separate experiments, error bars represent the standard 
error of the mean. 
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Figure 41: The effect of NCX-911 in reducing the phenylephrine-induced tone in human corpus 
cavernosum in the absence (CONTROL, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares). Each data point represents mean of eight separate experiments, error bars represent the standard 
error of the mean. 
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3.55 The effect of NCX-911 on phenylephrine-induced tone in human corpus 
cavernosum in the presence and absence of ODQ 
 
Increasing concentrations of NCX-911 (1 nM - 300 µM) were added to construct 
the concentration–response curves in the absence or presence of an inhibitor of an 
inhibitor of soluble guanylate cyclase, ODQ (10 µM) (Figure 42 and Table 4). In the 
presence of 10 µM ODQ, NCX-911 failed to induce a significant relaxation below 1 µM. 
Above 1 µM, NCX-911 could only reach 50% of the tone resulting in a significant 
rightward and upward shift in the concentration–response curve. The EC50 value for 
NCX-911 in the presence of ODQ was 6578.0±1150.0 nM (n=6, Figure 42 and Table 6).  
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Figure 42: The effect of NCX-911 in reducing the phenylephrine-induced tone in human corpus 
cavernosum in the absence (control, solid squares) or presence of 500 µM L-NAME (+L-NAME, open 
squares) or 10 µM ODQ (+ODQ, triangles). Each data point represents mean of at least six separate 
experiments, error bars represent the standard error of the mean. 
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Rabbit 
 
EC50 mean ± s.e.m. (nM) n 
NCX-911 997.8  ± 195.7 8 
 
+ L-NAME 500 µM 1281.2 ± 268.3 8 
 
Sildenafil 1000.5 ± 140.8 10 
+ L-NAME 500 µM    4959.1 ± 882.1* 8 
Spermine-NONOate 843.3 ± 54.4 
 
8 
+ L-NAME 500 µM 698.4 ± 61.8 8 
 
Table 5: EC50 values of NCX-911, sildenafil and spermine-NONOate for reducing phenylephrine-induced 
tone in the rabbit corpus cavernosum. n denotes the number of animals used for each set of experiments. 
*P<0.05 vs. sildenafil in the absence of L-NAME. 
Human 
 
EC50 mean ± s.e.m. (nM) n 
NCX-911 733.09 ± 94.4 8 
 
+ L-NAME 500µM 980.4 ± 106.7 8 
 
+ ODQ 10µM 6578 ± 1150** 6 
 
Sildenafil 800.7 ± 155.8 
 
10 
+ L-NAME 500µM 2446.7 ± 256.8* 
  
6 
+ ODQ 10µM 6488 ± 938** 
 
6 
Spermine-NONOate 1220.54 ± 19.27 6 
 
Table 6: EC50 values of NCX-911, sildenafil and spermine-NONOate for reducing phenylephrine-induced 
tone in human corpus cavernosum. n denotes the number of patients used for each set of experiments. 
*P<0.05 vs. sildenafil in the absence of L-NAME. ** P<0.05 vs. sildenafil or NCX-911 in the absence 
ODQ (10 µM) 
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3.6 Investigation of the effect of NCX-911 on nitrergic relaxations 
 
Since above 100 nM NCX-911 was able to reduce the phenylephrine-induced 
tone and it is not possible to elucidate the nitrergic relaxation responses at reduced tone, 
two concentrations (10 and 30 nM) were chosen to study the effect of the compound on 
nitrergic responses. At those sub-threshold concentrations NCX-911 was found to 
potentiate both the duration and magnitude of the relaxation responses (n=6) (Figure 43A 
and 44; 30 nM shown).  
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3.61 Investigation of the effects of sildenafil on nitrergic relaxations 
 
At sub-threshold concentrations of sildenafil (10 and 30 nM) the duration and 
magnitude of the nitrergic relaxation responses were potentiated (n=6) (Figure 43B and 
44; 30 nM shown).  
 
 
 
Figure 43: The effect of NCX-911 (a) or sildenafil (b), both at 30 nM, on the nitrergic responses of the 
rabbit corpus cavernosum. Each dot represents EFS (50 V, 0.3 ms pulse duration, for 5 s) at indicated 
frequencies. 
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Figure 44: The effect of NCX-911 (solid circles), sildenafil (open circles) or control (solid squares), all at 
30 nM, on the nitrergic relaxation responses of the rabbit corpus cavernosum. *P<0.05, significantly 
different from control. The difference between NCX-911- and sildenafil-induced potentiation was not 
significant. 
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3.62 Investigation of the effects of sildenafil and NCX-911 on blocked nitrergic 
responses 
 
After the nitrergic relaxations were blocked by L-NAME (500 µM), the 
administration of increasing concentrations of both sildenafil and NCX-911 were found 
to result in a decrease in the phenylephrine-induced tone as mentioned above, however 
nitrergic responses were not observed to appear again (n=6) (Figure 45).  
?
Figure 45: Two representative tracings showing the effect of NCX-911 (upper panel) or sildenafil (lower 
panel) on the tone and blocked nitrergic responses of the rabbit corpus cavernosum. EFS (indicated by dots; 
50V, 0.3ms pulse duration, 5 Hz, for 5 s, every 120 s) elicited nitrergic responses that were completely 
inhibited by L-NAME (500 µM). NCX-911 or sildenafil lowered the tone; however they failed to reverse 
the inhibition of the nitrergic responses. 
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3.7 Investigation of the effects of sildenafil, NCX-911 and BAY 41-2272 on the rat 
anococcygeus muscle  
 
3.71 Body weight and serum glucose concentrations 
The average body weight and serum glucose concentrations were measured at the 
beginning and at the end of 16 weeks. Both the weight and glucose concentrations were 
found to be similar between the two groups before the STZ injection.  
Sixteen weeks after the STZ injection, in comparison to the control group, the 
STZ injected group gained less weight and had higher serum glucose concentrations 
(Table 7). 
 
Time Control Group 
n=16 
Diabetic Group 
n=16 
 
0 week 
 
227.8±5.9 g 
5.2±0.5 mM 
 
228.9±8.7 g 
4.9±0.5 mM 
 
 
16th week 
 
552.4±20.6 g 
5.1±0.8 mM 
 
 
264.3±17.8 g * 
50.7±2.7 mM * 
 
Table 7: The body weight (upper value) and serum glucose concentrations (lower value) of control (saline-
injected) and diabetic (STZ-injected) rats at 0 (before the injection) and at 16th week. *P<0.05 significantly 
different from control group at 16th week. 
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3.8 Investigation of phenylephrine-induced tone 
The application of phenylephrine (0.01-30 µM) on rat anococcygeal strips 
produced concentration-dependent elevation of the tone of the tissue. The EC80 for 
phenylephrine was 1 µM in both the control and diabetic groups (n=8 for both) (Figure 
46). This concentration of phenylephrine was used in the following experiments to 
elevate the tone. 
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Figure 46: Concentration-response curve to phenylephrine in strips of anococcygeus muscles from control 
(CONTROL, solid squares) and STZ-injected (16 WEEK DIABETICS, open squares) rats. EC80 values for 
phenylephrine (1 µM for both groups) were calculated using this curve. Each data point represents mean of 
eight separate experiments, error bars represent the standard error of the mean. 
 
 118
3.81 Investigation of the effect of sildenafil on phenylephrine-induced tone 
The addition of increasing concentrations of sildenafil (0.001-300 µM) elicited 
concentration-dependent reductions of the phenylephrine-induced tone in tissues obtained 
from control animals with an EC50 of 827.1±167.3 nM (n=6) (Figure 47 and Table 8).  
In the diabetic animals the potency of sildenafil to reduce the phenylephrine-
induced tone was significantly lower than the control animals (n=6) (Figure 47). The 
EC50 values for sildenafil to reduce the phenylephrine-induced tone in diabetic animals 
was 2842.2±640.3 nM (p<0.05 vs. control) (Figure 47 and Table 8).  
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Figure 47: The effect of sildenafil in reducing the phenylephrine-induced tone in anococcygeus muscles 
from control (non-diabetic; solid squares) and 16 weeks diabetic (open squares) rats. Each data point 
represents mean of at least six separate experiments, error bars represent the standard error of the mean. 
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3.82 Investigation of the effect of NCX-911 on phenylephrine-induced tone 
The addition of increasing concentrations of NCX-911 (0.001-30 µM) reduced the 
phenylephrine-induced tone in a concentration-dependent manner in tissues obtained 
from control animals with an EC50 of 1088.8±165 nM (n=6) (Figure 48). In the diabetic 
animals the potency of NCX-911 was not significantly different from control animals 
(EC50 = 1765.9±303.5 nM, n=6, Figure 48, Table 8).  
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Figure 48: The effect of NCX-911 in reducing the phenylephrine-induced tone in anococcygeus muscle 
from control (non-diabetic; solid squares) and 16 weeks diabetic (open squares) rats. Each data point 
represents mean of at least six separate experiments, error bars represent the standard error of the mean. 
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3.83 Investigation of the effect of BAY41-2272 on phenylephrine-induced tone 
The addition of increasing concentrations of BAY41-2272 (1 nM-10 µM) 
produced concentration-dependent reductions of the phenylephrine-induced tone in 
tissues obtained from control animals with an EC50 of 151.6±9.3 nM (n=6) (Figure 49).  
 In the diabetic animals the potency of BAY41-2272 was not significantly different 
from the control animals. The EC50 value for BAY41-2272 to reduce the phenylephrine-
induced tone in diabetic animals was 209.7±27.3 nM (n=6, p>0.05 vs. control; Figure 49, 
Table 8).  
1 10 100 1000 10000
0
20
40
60
80
100
 Control
 16 week Diabetics
TO
NE
 (%
 o
f c
on
tro
l)
Log Concentration BAY 41-2272 (nM)
 
Figure 49: The effect of BAY41-2272 in reducing the phenylephrine-induced tone in anococcygeus 
muscles from control (non-diabetic; solid squares) and 16 weeks diabetic (open squares) rats. Each data 
point represents mean of at least six separate experiments, error bars represent the standard error of the 
mean. 
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Compound Group EC50 ± s.e.m. (nM) 
 
n 
NCX-911 
 
Control 1088.8±165.0  6 
 Diabetic  1765.9±303.5 
 
6 
BAY41-2272 
 
Control 151.6±9.3 6 
 Diabetic 209.7±27.3  
 
6 
Sildenafil Control 
 
827.1±167.3 6 
 Diabetic 2842.2±640.3* 
 
6 
 
 
Table 8: EC50 values (nM) of NCX-911, BAY41-2272 and sildenafil to reduce phenylephrine-induced tone 
in the anococcygeus muscle from control and diabetic rats. n denotes the number of animals used for each 
set of experiments. *P<0.05 significantly different from control group for the same compound. 
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3.9 Nitrergic relaxation responses in the rat anococcygeus muscle 
After treatment of the tissues with scopolamine (10µM) and guanethidine (10µM) 
and elevation of tone with phenylephrine (1µM, EC80), electrical field stimulation (EFS) 
(50 V, 0.3 ms pulse duration, 0.5-25 Hz, for 5 s, every 120 s) elicited reproducible 
contractions of the tissues (Figure 50). The optimum EFS-elicited frequency-dependent 
relaxation responses were seen at a frequency of 5 Hz (Figure 51). These relaxations 
were completely inhibited with an inhibitor of sGC (ODQ; 10 µM), an inhibitor of NO 
synthase (L-NAME; 500µM) (Figure 52) or tetrodotoxin (1 µM) indicating that they 
were nitrergic in nature and neurogenic in origin.  
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Figure 50: EFS (50 V, 0.3 ms pulse duration, 0.5-25 Hz, for 5 s, every 120 s, denoted with solid dots) of 
rat anococcygeus muscle elicited contractions. The addition of scopolamine and guanethidine at 10 µM 
abolished these contractions. The further addition of phenylephrine at 1 µM (EC80) elevated the tone and 
allowed the demonstration of NANC relaxation responses. In this trace the baseline, sensitivity and the 
speed of the recorder were adjusted (as denoted by arrow) to allow the full responses to be demonstrated on 
the trace. 
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Figure 51: After the addition of scopolamine and guanethidine at 10 µM and phenylephrine at 1 µM, EFS 
elicited NANC relaxation responses. Different frequencies of EFS (0.5-25 Hz) were then applied to assess 
the optimum frequency for EFS-induced relaxation responses. The black dot indicates when the EFS was 
applied. 
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Figure 52: The addition of scopolamine and guanethidine at 10 µM and phenylephrine at 1 µM (EC80) 
allowed EFS (50 V, 0.3 ms pulse duration, 0.5-25 Hz, for 5 s, every 120 s) to produce reproducible 
frequency-dependent relaxations. In the trace EFS at 25, 0.5 and 5 Hz frequencies is shown. The black dot 
indicates when the EFS was given. The addition of L-NAME at 500 µM resulted in complete inhibition of 
nitrergic relaxations and elevation of the tone. 
 
In the anococcygeus muscle from diabetic animals, there was a significant 
reduction in the magnitude of nitrergic relaxations at all frequencies in comparison to 
control animals (Figures 53 and 54). At the highest frequency (25 Hz) almost 80% of the 
relaxation response was lost in the diabetic group (Figures 53 and 54). 
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Figure 53: Electrical field stimulation (50 V, 0.3 ms pulse duration, for 5 s, indicated by solid circles) at 
variable frequencies (0.5-25 Hz; as indicated) elicited nitrergic relaxation responses in the anococcygeus 
muscle from control (left) and 16 weeks diabetics (right) rats. The dotted line represents the basal tone. 
 
 
 
 
 
Figure 54: Electrical field stimulation (50 V, 0.3 ms pulse duration, for 5 s)-induced nitrergic relaxation 
responses were significantly attenuated in the diabetic group (circles) compared to control group (squares). 
*P<0.05 significantly different from control group at the same frequency. 
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3.91 Investigation of the effect of sildenafil, NCX-911 and BAY41-2272 on nitrergic 
relaxations in the rat anococcygeus muscle 
 
Since above certain concentration all three compounds were able to reduce the 
phenylephrine-induced tone and it is not possible to elucidate the nitrergic relaxation 
responses at reduced tone, two sub-threshold concentrations (10 and 30 nM) of each 
compound were chosen to study the effect of the compound on nitrergic responses. At 
these sub-threshold concentrations the compounds were found not to reduce the tone but 
were found to potentiate both the duration and magnitude of the nitrergic relaxation 
responses in the control group (not shown).  
In the diabetic group the magnitude and duration of the remaining nitrergic 
response was potentiated by BAY41-2272 (30 nM) but not by sildenafil (30 nM) or 
NCX-911 (30 nM) (Figure 55). The average potentiation of the nitrergic response at 5 Hz 
by 30 nM BAY41-2272 was found to be 183.5±22.1% when the area under the curve of 
relaxation was evaluated (n=6). 
  
 
 
 
 
 
 
 128
 
Figure 55: The effect of sildenafil, NCX-911 and BAY41-2272 (all at 30 nM) on the nitrergic responses in 
the anococcygeus muscle from diabetic rats. Electrical field stimulation (50 V, 0.3 ms pulse duration, 5 s, 5 
Hz) is denoted by solid circles. Note the potentiating effect of BAY41-2272 on both magnitude and 
duration of the response (n=6). 
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CHAPTER 4. 
 
DISCUSSION 
 130
4.0 Discussion 
 
Despite major advances in the understanding of the physiology of penile erection 
and the pathophysiology of ED, together with an increase in the armamentarium of 
medications available, ED remains a significant global male health problem. This 
condition greatly affects patient quality of life and self-esteem. Moreover there is also 
evidence that ED negatively impacts on the ability to maintain intimate relationships. 
New oral medications especially the phosphodiesterase type 5 (PDE5) inhibitors 
have revolutionalised the treatment of ED by decreasing reliance on more invasive 
options. Three potent selective PDE5 inhibitors, sildenafil (Viagra; Pfizer), tadalafil 
(Cialis; Lilly), and vardenafil (Levitra; Bayer) are currently available in the UK. 
Although large multi-centre clinical trials have shown the efficacy and tolerability of 
these drugs in ED with various aetiologies and a broad range of severity, 30-35% of 
patients fail to respond (Moore et al., 2005). Studies which have assessed the long term 
uptake of PDE5 inhibitors report a renewal rate of 62% for prescriptions at three to four 
months of follow-up. However this level fell back to around 30% by 6-12 months 
(McMahon et al., 2006).  
The possible reasons for acute or delayed failure include severe ED at 
presentation, worsening of endothelial dysfunction, ED after radical prostatectomy or 
diabetes, unrecognised or untreated hypogonadism, inadequate patient education or 
incorrect drug usage and the development of drug tolerance.  
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ED and diabetes 
There is now ample evidence to suggest that ED is common in men with diabetes. 
It has been reported to affect up to 32% with type 1 and 46% of type 2 diabetic men 
(Vickers and Wright, 2004). Analysis of the results from the Massachusetts Male Ageing 
Study (MMAS) demonstrated that diabetics are three times as likely to have ED than 
non-diabetic men (Feldman et al., 1994). In the study, the prevalence of ED varied from 
33 to 75% depending on age, the glycaemic control and the presence of additional risk 
factors (e.g. smoking, hypertension, hyperlipidaemia) (Feldman et al., 2000). 
Importantly, it is now recognised that ED can be the first manifestation of previously 
undiagnosed diabetes (Sun et al., 2006). This of course further supports the importance of 
risk factor screening on first presentation.  
As previously discussed, the pathophysiology of ED in diabetes is multifactorial 
(See 1.3.5). The proposed mechanisms in diabetic patients includes elevated advanced 
glycation end-products (AGEs) (Cartledge et al., 2001a) and increased levels of oxygen 
free radicals (Cartledge et al., 2001a), impaired NO synthesis (Cartledge et al., 2001b), 
increased endothelin B receptor binding sites and ultra structural changes (Sullivan et al., 
1997), an up regulated RhoA/Rho-kinase pathway (Bivalacqua et al., 2004), NO-
dependent selective nitrergic nerve degeneration (Cellek et al., 1999) and impaired cyclic 
guanosine monophosphate (cGMP)-dependent kinase-1 (PKG-1) (Chang et al., 2004).  
It is now well established that nitrergic function is impaired in diabetic patients 
with ED (Saenz, I et al., 1989), in the corpus cavernosum of alloxan-induced diabetic 
rabbits (Azadzoi and Saenz, I, 1992) and in the corpus cavernosum and anococcygeal 
smooth muscle of streptozotocin-induced diabetic rats (Rehman et al., 1997). 
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Furthermore, it has been demonstrated that the activity and amount of nNOS protein is 
reduced in functional and structural studies involving the corpus cavernosum of 
spontaneously diabetic BB/WORdp rats (Vernet et al., 1995). Strong subsequent evidence 
also demonstrates that the reduction in nNOS activity and protein is most likely to be 
secondary to selective nitrergic degeneration as this may be prevented by administration 
of an NOS inhibitor (Cellek et al., 1999). Further investigations have clarified that the 
defective nitrergic relaxation responses were not due to changes in the responsiveness of 
the smooth muscle to NO. The addition of an NO donor resulted in responses which were 
very similar between the control and diabetic tissues (Cellek et al., 1999). 
It is however likely that the processes of selective nitrergic degeneration and 
oxidative stress work closely together to produce the pathophysiological changes which 
result in diabetes-induced ED. Indeed some authors have suggested that the generation of 
the powerful pro-oxidants such as peroxynitrite in diabetes may directly result in ED by 
the process of selective nitrergic nerve loss (Lyall et al., 1998). Evidence from studies 
assessing the timing of insulin replacement in diabetes, shows that the loss of nNOS 
content is potentially reversible with early insulin replacement. This finding provides 
support to the theory that early on in the disease process there are non-structural reasons 
for nNOS loss such as a reduction in necessary growth factors or dysfunction axonal 
transport of nNOS protein from the neuronal cell body (Cellek et al., 2003). From the 
same study, when the diabetes is allowed to progress with time, underlying structural 
damage to nitrergic nerves occurs. Unfortunately, these changes are not reversible with 
insulin treatment. Moreover, as these results suggest a degenerative process in the nerve 
ganglia, this further supports a role for oxidative stress. The accumulation of factors that 
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cannot be reversed by insulin treatment and may ultimately result in irreversible nerve 
damage include the aforementioned advanced glycation end-products (AGEs). As 
described previously (See 1.3.5b), AGEs have been shown to accumulate during the 
course of diabetes and may therefore act together with endogenous NO to produce 
neuronal apoptosis and ultimately nitrergic degeneration (Cellek et al., 2003).  
 
Treatment of diabetic ED 
To achieve optimum results in this difficult to treat patient group, diabetic ED 
treatment should ideally involve a multimodal approach. Patients need to be carefully 
counselled with respect to treatment of the underlying hyperglycaemia and co-
morbidities. Studies have reported an improvement in erectile function after  glycaemic 
control is improved and other co-morbidities treated (Awad et al., 2009;El-Sakka et al., 
2009).  
According to the Second Princeton Consensus Conference (Jackson et al., 2006) it 
was recommended that the cardiovascular system should be assessed in all patients with 
ED prior to the initiation of any treatment. If this advice is followed, each patient may be 
assigned to one of three risk levels based on their cardiovascular risk. 
As previously mentioned (See 1.4.1), the PDE5 inhibitors are now the mainstay of 
oral medical treatment of ED in diabetic patients. These agents successfully inhibit PDE5, 
the primary phosphodiesterase enzyme in the corpus cavernosum tissue responsible for 
the degradation of cGMP (Beavo, 1995;Wallis et al., 1999). During sexual stimulation 
and arousal, the released NO activates soluble guanylate cyclase, which in turn catalyzes 
guanosine triphosphate to cGMP. Cyclic GMP causes by way of many processes a 
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decrease in cytosolic calcium concentration and the relaxation of smooth muscle (Kalsi et 
al., 2002). Thus, by inhibiting PDE5, there is a prolonged elevated concentration of 
intracellular cGMP and enhanced smooth muscle relaxation.  
In a study comparing sildenafil versus placebo in type 1 diabetics, there was 
reported to be significant improvements from baseline using several end points. When the 
ability to achieve erections (IIEF Q3) was assessed 35.7% were successful with sildenafil 
versus placebo (19.9%) whereas with the ability to maintain erections (IIEF Q4) 68.4% 
of patient had a positive outcome with sildenafil versus placebo (26.5%). Moreover, 
when a more crude measure of success was used such as the Global Assessment Question 
(GAQ) the results were 66.6% vs. 28.6% for sildenafil and placebo respectively (Stuckey 
et al., 2003).  
In a more recent but similar study with vardenafil, the baseline erectile function 
(EF) domain of IIEF score was 11.2, and it increased to 19.0 (69.6%), 17.1 (52.7%) and 
12.6 (12.5%) for vardenafil 20 mg, 10mg and placebo, respectively. In this study the 
results with the GAQ was 72% for vardenafil 20 mg, 57% for vardenafil 10 mg, and 13% 
for placebo. A more detailed evaluation of patients based on severity of baseline ED 
demonstrated that patients with severe ED (EF score < 11) had a 40% rate of successful 
intercourse with vardenafil 20 mg versus 11% for placebo. This compared with a higher  
rate of 75% success with vardenafil at 20 mg versus 47% for placebo success in patients 
with mild ED (EF score 22-25) had a (Goldstein et al., 2003).  
In a retrospective analysis from 12 placebo-controlled trials evaluating tadalafil, it 
was reported that patients with diabetes had a baseline of 12.6 for the EF domain of IIEF. 
Treatment with tadalafil at 10 mg and 20 mg was found to result in an increase in the 
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IIEF EF domain score of 6.2 and 7.4, respectively, versus 0.9 for placebo. The 
corresponding scores for the GAQ was 74.5% for tadalafil 20 mg 60.6% for 10 mg, and 
29.7% for placebo, respectively (Fonseca et al., 2004).  
In summary, all three PDE5 inhibitors have been evaluated in diabetic patients 
with similar levels of efficacy averaging 60-70%. However, there are at present no head-
to-head comparative trials and hence, efficacy comparisons cannot be performed due to 
different populations studied. In my clinical experience, diabetic men require the top dose 
of each agent, sildenafil 100 mg, vardenafil 20 mg and tadalafil 20 mg. Despite this a 
significant number of patients have poor results or fail therapy. Therefore, new 
therapeutic targets which may potentially relax cavernosal smooth muscle without the 
need of endogenous NO are needed. Therefore, sGC activators such as BAY41-2272 and 
NO releasing PDE5 inhibitors such as NCX-911 were investigated in this thesis in order 
to assess whether they could relax cavernosal or anococcygeal smooth muscle in NO 
deficiency. 
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The rabbit animal model 
In 1990, it was first reported that the relaxation of isolated rabbit corpus 
cavernosum smooth muscle by electrical stimulation was accompanied by the production 
of NO and cyclic GMP. This relaxation was prevented by treatment of tissues with NO 
synthase inhibitors, haemoglobin and methylene blue. However, treatment with 
indomethacin was not found to inhibit relaxation responses (Ignarro et al., 1990). These 
results were the first to suggest that relaxation of corpus cavernosum was mediated by 
non-adrenergic non-cholinergic (NANC) neurotransmitters and attributed to the 
generation and release of NO as the primary neurotransmitter. 
Since that time, the rabbit corpus cavernosum has been confirmed to be an 
excellent model for the investigation of erectile smooth muscle physiology (Cellek and 
Moncada, 1997b). The results obtained are reproducible and the tissue is easy to handle 
and mount. However, despite this reports suggest that rabbit corpus cavernosum shows a 
different phosphodiesterase profile to human cavernosal tissue (Qiu et al., 2000). Because 
of these differences, the experiments were repeated in human corpus cavernosal tissues 
for comparison and validation. 
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Human corpus cavernosum 
Following on from the work on rabbit corpus cavernosum, which demonstrated 
that penile erection is mediated by neuronal NO, additional studies revealed the same 
physiological mechanism for penile erection exist in human (Rajfer et al., 1992) and 
canine (Trigo-Rocha et al., 1993) corpus cavernosum. The main problems of using 
human corpus cavernosum tissue to perform in-vitro studies are associated with its 
limited availability further complicated by the heterogeneous source of the tissues used 
(Peyronie’s disease, ED, penile cancer). 
In this study I used human corpus cavernosum from patients undergoing gender 
re-assignment surgery. The men had been maintained on long-term oestrogen therapy 
before surgery to aid the development of secondary feminine characteristics. However 
oestrogen treatments were stopped 6 weeks before surgery in all patients. It has 
previously been demonstrated that gender reassignment is a reliable source of human 
tissue (Goepel et al., 1999). As the entire corpus cavernosum is obtained at the time of 
surgery, this allows a standardized procedure to prepare human corpus cavernosum strips. 
Furthermore, studies have also shown that the human tissue from gender re-assignment 
patients, if kept refrigerated does not lose its ability to contract to phenylephrine, 
angiotensin II and high potassium for many days (Mirone et al., 2000). Moreover, the 
human corpus cavernosum has been demonstrated to relax to endothelium-dependent and 
independent mechanisms as well as direct K(ATP) channel openers (cromakalim) after 
pre-contraction with phenylephrine (Mirone et al., 2000). The results obtained were very 
similar to those from human cavernosal tissue from non-gender change patients (Mirone 
et al., 2000). 
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Previous studies which have evaluated the relationship between the degree of 
corporeal smooth muscle contraction and the magnitude of the observed relaxation 
response (nitroglycerine, nitroprusside, and prostaglandin E1) suggest that the 
relationship between contraction and relaxation is linear with an inverse relationship. 
However, statistical analysis indicated that the slope of the regression line was 
significantly greater than unity in corporeal tissues obtained from patients with organic 
ED versus controls (Taub et al., 1993). These results provided evidence implicating 
heightened adrenergic tone as a significant aetiological factor in ED. To make sure that 
there was no significant difference in adrenergic tone between the human and rabbit 
corporeal tissues, concentration response curves in response to phenylephrine were 
constructed. The results showed that both tissues had very similar responses with an EC80 
to phenylephrine of 3M. 
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Diabetic animal model  
Both the rabbit and rat are good and reliable models for diabetes research. The 
cost and husbandry is significantly greater with rabbit when directly compared with rats. 
However, the rat penile corpus cavernosum is a difficult tissue to work with due to 
spontaneous contractions compared to the rat anococcygeus muscle. In contrast, the 
anococcygeus muscle (Cheah et al., 2002;Rand and Li, 1992;Rand and Li, 1993) has 
been widely accepted as ideal smooth muscle models to study not only nitrergic 
neurotransmission but also other NANC neurotransmitters (Kasakov et al., 1994;Rand 
and Li, 1992;Rand and Li, 1993). In the rat, the corpus cavernosum and the anococcygeus 
muscles receive motor sympathetic innervations via the lumbar sympathetic nerves and 
parasympathetic innervations via the sacral parasympathetic nerves. They therefore share 
a common origin for nitrergic and sympathetic pathways. Furthermore, the anococcygeus 
muscle, unlike the corpus cavernosum, is a purer smooth muscle preparation containing 
very few blood vessels making pharmacological experiments easier to interpret. 
Moreover, the anococcygeus was the first tissue in which a neurotransmitter role for NO 
was firmly established (Gillespie et al., 1989). 
By developing a rat anococcygeal model of diabetes, the potencies of the PDE5 
inhibitor (sildenafil), the NO-releasing sildenafil (NCX-911) and the sGC activator 
(BAY41-2272) could be assessed and compared in non-diabetic and diabetic rats. 
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Soluble guanylate cyclase activators 
Our knowledge of the function of soluble guanylate cyclase (sGC) has increased 
significantly during the past decade. The best studied class of sGC activators are organic 
nitrates which mimic the action of endogenous NO by bioconversion to NO or NO-related 
compounds. Organic nitrates are widely used in the treatment of angina pectoris. 
However, the use of such compounds is limited by a potential lack of response due to 
insufficient biometabolism (Li et al., 2006), development of tolerance following 
prolonged administration (Munzel et al., 2005) and non-specific interactions of NO with 
other biological molecules, including peroxynitrite-mediated tyrosine nitration (Dikalov 
et al., 1998). These reactions are difficult to control owing to the spontaneous release of 
NO from nitro-vasodilators and its free diffusion in biological systems. Furthermore, 
although there is symptomatic improvement in patients with cardiovascular disease 
treated with organic nitrates, there is no evidence that such treatment reduces mortality 
(Csont and Ferdinandy, 2005). Therefore compounds that activate sGC in an NO-
independent manner might offer considerable advantages over current therapies. 
The recent discoveries of compounds that stimulate sGC independently of NO 
allow this pharmacological target to be investigated more thoroughly. NO-independent 
but haem-dependent stimulators of sGC, as well as NO- and haem-independent sGC 
activators, are emerging as valuable tools that could help to elucidate the physiology and 
pathophysiology of the NO–sGC–cGMP pathway in many conditions including ED. 
In 1994, Ko and co-workers described an indazole derivative YC-1 (Ko et al., 
1994), which was subsequently characterized as an NO-independent, haem-dependent 
stimulator of highly purified sGC (Mulsch et al., 1997). It was found to stimulate sGC 
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directly via a distinct mechanism and sensitize the enzyme towards its native activator 
NO (Friebe and Koesling, 1998). YC-1 has also been shown also to act as a non-specific 
phosphodiesterase inhibitor (Friebe et al., 1998) and to stimulate the synthesis and release 
of NO (Wohlfart et al., 1999).  
YC-1 has been shown to relax rabbit cavernosal strips (EC50 = 8.5 M) via 
increasing cGMP levels (Nakane et al., 2002). Systemic injection of YC-1 has been 
shown to enhance penile erection in the rat and to induce erection when injected 
intracavernously (Mizusawa et al., 2002). In vitro YC-1 enhances EFS-induced 
relaxations in the rat corpus cavernosum (Nakane et al., 2002) and enhances relaxations 
induced by an NO donor in rabbit corpus cavernosum (Mizusawa et al., 2002).  
Using YC-1 as a lead compound, BAYER AG embarked upon a chemical 
optimization programme of 2,000 newly synthesized compounds in search for more 
potent NO-independent sGC activators. This resulted initially in the discovery of a 
pyrazolopyridine derivative, 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-Hpyrazolo[3,4-
b]pyridin-3-yl]-pyrimidin-4-ylamine (BAY41-2272) which was identified using a photo 
affinity label on the purified enzyme (Stasch et al., 2001). The cysteine 238 and cysteine 
243 spanning regions in the α1-subnunit of sGC were subsequently identified as part of 
the target site. Because of the structural similarity between BAY41-2272 and YC-1, it 
was initially thought that both compounds may act by the same mechanism. However, in 
contrast to YC-1, BAY41-2272, up to 10µM, is devoid of any PDE5 inhibitory activity 
(Stasch et al., 2001).  More recently a further pyrazolopyridine derivative BAY41-8543 
has also been identified (Stasch et al., 2002a).  
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Effect of BAY41-2272 on human and rabbit corpus cavernosum 
 
In this study I have shown that BAY41-2272 lowers the phenylephrine-induced 
tone in the human and rabbit corpus cavernosum with an EC50 of approximately 400-500 
nM. This is in agreement with a previous study where EC50 of the compound to relax 
rabbit aortic rings was 304±63 nM (Stasch et al., 2001). The potency of BAY41-2272 on 
lowering phenylephrine-induced tone was twice more than an NO donor (spermine-
NONOate) and 32 times more than YC-1. These results confirm that BAY41-2272 has a 
similar potency to NO and is significantly more potent than YC-1 as shown previously 
(Stasch et al., 2001) . It has been suggested that metabolites of BAY 41-2272 may retain 
the ability to activate sGC, and may therefore contribute to the greater in vivo activity 
(Straub et al., 2002). 
 
Other groups have reported results with BAY41-2272 in rabbit and human 
cavernosal tissues with significantly different potencies to my observations (Baracat et al., 
2003). They ascribe this to the use of cavernosal tissue from healthy multiple organ 
donors and suggest that my results are because of the use of oestrogenised tissues. 
However, their results are significantly different to mine in both human and rabbit tissues 
so the differences are most likely to be methodological. 
My results have shown that the relaxant effect of BAY41-2272 is significantly 
inhibited by a sGC inhibitor (ODQ) suggesting that the effect of BAY41-2272 is sGC-
dependent. However, in both rabbit and human corpus cavernosum, the relaxations 
elicited by BAY41-2272 were only partially affected by ODQ at concentrations which 
can block the nitrergic relaxations (30 µM). Interestingly, even in the purified enzyme, 
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ODQ has previously been shown to fail to abolish the BAY41-2272-induced sGC 
activation (Stasch et al., 2001). My results are also in accordance with previous studies 
where the activation of sGC by YC-1 (Martin et al., 2001) and BAY41-2272 (Becker et 
al., 2001b) was not completely blocked by ODQ. This may be attributed to the possibility 
that the binding of ODQ and sGC activators to the sGC are not mutually exclusive 
processes and that their binding sites do not overlap. Moreover, non-NO-based sGC 
activators have haem-dependent and -independent activities (Becker et al., 2001b;Martin 
et al., 2001). Moreover, ODQ has been described to oxidize the haem moiety of sGC. It 
may also have an allosteric mechanism by interfering with the binding of BAY 41-2272, 
through changes in the secondary structure of the recombinant enzyme when ODQ is 
added to the NO-stimulated sGC (Kosarikov et al., 2001). 
In contrast, in my study the relaxation response to the NO donor, spermine-
NONOate was found to be completely blocked by ODQ. This is in accordance with 
previous studies which have demonstrated that  relaxation of the corpus cavernosum by 
exogenous or endogenous NO was abolished by ODQ (Nakane et al., 2002). In these 
studies, responses elicited by an NO donor, glyceryl trinitrate and by acetylcholine, 
which releases NO from the sinusoidal endothelium, were fully prevented by ODQ 
(Baracat et al., 2003). It has been suggested that the inhibitory effect of ODQ on NO-
stimulated sGC is as a result of changes in the oxidation state of the haem moiety, 
without significant effects in the catalytic activity of the enzyme (Zhao et al., 2000). 
My results demonstrated that the concentration-relaxation response curve to 
BAY41-2272 was shifted to the right with the addition of an inhibitor of NO synthase 
suggesting that the endogenous basal NO levels could be potentiating the effect of the 
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sGC activator. Indeed stimulation of purified sGC by BAY41-2272 has previously been 
shown to be enhanced by an NO donor (Stasch et al., 2001). Interestingly, my results 
indicate that BAY41-2272 enhances nitrergic relaxations at concentrations known to have 
no PDE-inhibitory activity. These findings further support the concept that BAY41-2272 
synergizes with endogenous NO. When I completely blocked nitrergic relaxations with 
the NO synthase inhibitor, only high concentrations of BAY41-2272 could reverse the 
inhibition confirming the PDE-inhibitory action of the compound at high concentrations. 
This in accordance with a recent in vitro study where concentrations of BAY41-2272 
several orders of magnitude above those needed for sGC stimulation resulted in some 
degree of PDE5 inhibition (IC50 = 3 M) (Mullershausen et al., 2004). However, this 
remains many orders of magnitude higher than that required to cause relaxation in a 
number of isolated tissues including aorta (Priviero et al., 2005), vaginal wall (Cellek, 
2003), and corpus cavernosum (Kalsi et al., 2003) (EC50 = 0.06–0.49 M). Furthermore, 
studies using recombinant sGC revealed that concentrations of BAY41-2272 as low as 
0.01–0.1 M stimulate sGC to a level that would usually be expected to cause 
biologically and clinically important increases in cGMP (Stasch et al., 2001).  Moreover, 
in vivo studies provide further evidence against a role for PDE-5 inhibition in the action 
of BAY 41-2272 (Evgenov et al., 2004).  
In conclusion, my results clearly demonstrate that the sGC activator BAY41-2272 
can relax human and rabbit corpus cavernosum. The relaxant effects of BAY 41-2272 
synergize with endogenous NO. In the total absence of endogenous NO the compound is 
still able to relax the smooth muscle and to reverse the inhibition of nitrergic relaxations. 
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Therefore, sGC activators may be a novel way of treating male ED particularly in 
patients where endogenous NO production is dysfunctional. 
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Nitric oxide and PDE5 inhibitors 
It is now generally accepted that the most critical step in penile erection is 
relaxation of penile cavernosal and vascular smooth muscle (Andersson and Wagner, 
1995). Moreover, the role of NO is of fundamental importance in this process. NO has 
been shown to induce an increased production of the second messenger cGMP via 
stimulation of the enzyme sGC in the penile smooth muscle. In turn cGMP has been 
shown to activate a number of downstream pathways, ultimately resulting in relaxation of 
the cavernosal smooth muscle (Andersson, 2001a). 
Several synthetic NO donors have been tested in clinical trials or on experimental 
animal studies, on the premise that the release of exogenous NO would allow corporal 
smooth muscle relaxation. Although sodium nitroprusside (SNP) substantially relaxes 
pre-contracted preparations in vitro, contrasting results have been obtained in vivo by 
directly injecting NO donors into the corpora cavernosum in erectile dysfunction (Truss 
et al., 1994;Wang et al., 1994;Wegner and Knispel, 1993). 
 A new class of NO donors has recently been synthesized, which consists of nitro-
derivates of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin (NO-
NSAIDs) (Fiorucci et al., 2004). A common chemical feature of these compounds is a 
link of an effective moiety with nitrate through a spacer. It has been reported that these 
agents are chemically stable, but are able to subsequently release NO enzymatically after  
exposure to biological tissues (Keeble & Moore, 2002). One such example is NCX-4050, 
which has been shown to allow the release of low concentrations of NO in a controlled 
manner (Filippi et al., 2003a).  
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It has therefore been suggested that the administration of an NO donor with 
sildenafil may compensate for reduced “NO drive” in vasculopathic states (Jeremy et al., 
1997;Kalsi et al., 2004;Kalsi et al., 2005;Seidler et al., 2002).  
Using the same basic principles as above, novel agents which are combinations of 
a PDE5 inhibitor and NO-releasing compounds have been produced. NCX-911 (sildenafil 
nitrate) is one such agent. It has been shown to have a similar potency to sildenafil and 
release NO spontaneously (Riffaud JP, 2001).  It was my aim to investigate the effect of 
NCX-911 on the tone and nitrergic responses of rabbit and human corpus cavernosum 
and compare the effects with that of sildenafil and an NO donor (spermine-NONOate). 
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The effect of NCX-911 and sildenafil on human and rabbit corpus cavernosum 
The results of this study have revealed that NCX-911 lowers the phenylephrine-
induced tone in rabbit and human corpus cavernosum with an EC50 of approximately 
733-997 nM. This is in agreement with a previous study where the EC50 of the NCX-911 
to relax human corpus cavernosum was in the range of 1-10 µM (Seidler et al., 2002).  
My results also demonstrate that the potency of NCX-911 on lowering 
phenylephrine-induced tone was similar to both sildenafil and the NO donor  in control 
tissues. These results are in disagreement with a previous study where NCX-911 was 
reported to be more potent than sildenafil at relaxing human cavernosal strips from 
gender reassignment surgery pre-contracted with noradrenaline (Seidler et al., 2002). 
However, since the potencies of NCX-911 and sildenafil were not detailed with exact 
EC50 values in that study, the degree of separation between the two compounds is 
difficult to evaluate. The disparity between the results of that study and mine could be as 
a result of different techniques used. Seidler et al (Seidler et al., 2002) used organ baths 
whereas I used superfusion chambers. It is possible that superfusion of corpus 
cavernosum might cause a higher shear stress compared to the organ bath and therefore 
cause a greater release of NO from the endothelium.  
In this study, I established that the treatment of human and rabbit cavernosal strips 
with an inhibitor of NO synthase (L-NAME), at a concentration known to block 
endogenous NO production (Cellek and Moncada, 1997b;Kalsi et al., 2003), resulted in a 
significant rightward shift of the concentration-response curve to sildenafil (a 5-fold 
reduction in potency), but not that of NCX-911 or the NO donor. These results suggest 
that sildenafil requires endogenous NO to relax cavernosal smooth muscle. This is in 
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accordance with a previous study where sildenafil was shown to be unable to potentiate 
the reduced erectile responses in mice lacking the neuronal NO synthase enzyme (Cashen 
et al., 2002). However, they are in disagreement with another study which demonstrates 
that sildenafil citrate may have a direct relaxant effect on cavernosal tone at 
concentrations of 100 nM or greater (McAuley et al., 2001). These authors proposed this 
effect was independent of the NO–cGMP pathway, as the effect was not able to be 
inhibited with L-NAME and only partially prevented by oxadiazolo quinoxaline (ODQ), 
a guanylate cyclase inhibitor (McAuley et al., 2001). Other studies suggest that the 
mechanism of sildenafil-induced relaxation may entail, in part, the suppression of 
superoxide formation (Shukla et al., 2005). However, the possible direct relaxation of 
cavernosal tissue by sildenafil may be actually be a result of basal production of cGMP 
which may accumulate to exert a significant modulating effect on cavernosal smooth 
muscle tone in the presence of PDE5 inhibition. This basal cGMP production may be 
produced by the basal release of NO. Unfortunately the group investigating this 
phenomenon could not answer whether the basal cGMP production is due to stimulation 
by NO as they did not treat cavernosal tissue strips with both L-NAME and ODQ 
(McAuley et al., 2001). 
As there was no change in the potency of NCX-911 in either rabbit or human 
cavernosal tissues with an inhibitor of NO synthase (L-NAME), the results of this study 
clearly demonstrate that NCX-911 does not require endogenous NO to cause relaxation 
of human and rabbit corpus cavernosum. My results further confirm the difference 
between the two compounds NCX-911 and sildenafil.  
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The results seen with NCX-911 and sildenafil in my study are in accordance with 
a previous study where endogenous NO production was reduced in a 
hypercholesterolemia rabbit model and NCX-911 was reportedly 5-10 times more potent 
than sildenafil citrate in reducing phenylephrine-induced tension (Riffaud JP, 2001). 
Furthermore, in anaesthetized rats, cavernous nerve-stimulation resulted in increases in 
intracavernous pressure. This pressure rise was shown to be enhanced by intravenous 
administration of both sildenafil and NCX-911, however at sub-maximal stimulation 
NCX-911 was found to be more potent than sildenafil (Riffaud JP, 2001).  
 
In the presence of an inhibitor of sGC (ODQ), my results demonstrated that the 
concentration-response curves to both NCX-911 and sildenafil were both shifted to the 
right and upward. These results suggest that both compounds require an active sGC 
enzyme to exert their effects. However, the inhibitory effect of ODQ was only partial; at 
concentrations above 1 M both NCX-911 and sildenafil induced relaxation responses 
reached up to 50% of the maximum. This is in accordance with other previous studies 
where ODQ partially inhibited sildenafil-induced relaxation responses in human corpus 
cavernosum (Baracat et al., 2003) and failed to completely inhibit intracavernous 
sildenafil-induced erection in rabbits (McAuley et al., 2001).  
The NO donor NCX4050 belongs to a novel class of drugs called NO-NSAIDs 
characterized by the ability to release low concentrations of NO, in a controlled manner. 
This is in contrast to NCX-911 where NO is released spontaneously. A common chemical 
feature of this novel drug class is a link of an effective moiety with nitrate through a 
spacer. As previously discussed, it is reported that they are chemically stable agents but 
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are able to release NO after enzymatic change following exposure to biological tissues 
(Keeble and Moore, 2002). 
 In rabbit and human corpus cavernosum, NCX-4050 has previously been shown 
to be able to relax cavernosal tissues with an efficacy similar to sodium nitroprusside 
(SNP) (IC50 = 21 ± 1.7 M, IC50 = 19 ± 2.3 M, in rabbit and human respectively) 
(Filippi et al., 2003a). In contrast to SNP the relaxant responses to NCX-4050 were 
reported to develop more slowly. In accordance to the results seen with NCX-911 in my 
study, it was also observed that ODQ antagonized the relaxant response induced by 
NCX-4050. However, even at high concentrations of ODQ, NCX-4050 was still able to 
produce some relaxation responses (IC50 = 2587 ± 312 M) (Filippi et al., 2003a). Again, 
these observations suggest that there may an alternative direct relaxing effect of these 
compounds which is not related to amplification of the NO-cGMP system. 
I found that both NCX-911 and sildenafil increased the magnitude and the 
duration of nitrergic relaxations with similar potencies in the rabbit corpus cavernosum. 
These results suggest that both compounds have similar mechanisms of action and 
properties under control conditions despite the differences in chemical structure. In my 
study, the release of NO from the NCX-911 compound did not seem to further potentiate 
the nitrergic relaxations in rabbit corpus cavernosum. 
In my study, in the presence of an inhibitor of NO synthase (L-NAME), the 
nitrergic relaxations were completely inhibited in the rabbit corpus cavernosum. 
Increasing concentrations of NCX-911 or sildenafil were not able to reverse the loss of 
nitrergic relaxations. This is in contrast to the effect of a NO-independent sGC activator, 
BAY41-2272 (Kalsi et al., 2003). This compound is able to reverse the loss of nitrergic 
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relaxation at concentrations greater than 300 nM. BAY41-2272 has been shown to bind to 
an allosteric site on the sGC enzyme different to the binding site for NO (Stasch et al., 
2001). It has been suggested that this binding at the allosteric site may lead to a 
conformational change such that there is an increased affinity for NO. The 
conformational change may be responsible for the reversal of inhibition of nitrergic 
relaxations. In contrast, there are no reported conformational changes associated with the 
addition of either a PDE5 inhibitor or an NO donor. 
In conclusion, my results suggest that NCX-911 is a potent relaxant with a similar 
potency to NO. It is equally efficacious with respect to relaxation of rabbit and human 
corpus cavernosum independent of NO availability. Like PDE5 inhibitors, NCX-911 
potentiates both the duration and magnitude of the nitrergic relaxation. Therefore, NCX-
911 may be a novel way of treating male ED particularly in patients where endogenous 
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NO and diabetes mellitus 
Nitric oxide released from sinusoidal endothelium and postganglionic cholinergic 
(nitrergic) nerve fibres is the major mediator of vascular and cavernosal smooth muscle 
relaxation in the penis (Andersson, 2001b). In diabetes the NO-mediated responses have 
been shown to be reduced in both human and animal studies (Azadzoi and Saenz, I, 
1992;Pickard et al., 1994;Pickard et al., 1995;Rehman et al., 1997;Saenz, I et al., 1989).  
As previously described (See 1.3.5b), this has been attributed to elevated 
advanced glycation end-products (AGEs) and increased levels of oxygen free radicals 
(Cartledge et al., 2001a) which may lead to decreased bioavailability of NO (Jones et al., 
2002), impaired NO synthesis due to down-regulation of eNOS/nNOS expression 
(Akingba and Burnett, 2001;Podlasek et al., 2001;Vernet et al., 1995), decreased and 
impaired cyclic guanosine monophosphate (cGMP)-dependent kinase-1 (PKG-1) (Chang 
et al., 2004), increased endothelin B (ETB) receptor binding sites and ultrastructural 
changes (Sullivan et al., 1997), up-regulated RhoA/Rho-kinase pathway (Bivalacqua et 
al., 2004), and NO-dependent selective nitrergic nerve degeneration (Cellek et al., 
2003;Cellek et al., 1999;El-Sakka et al., 1999).  
The decreased production and/or availability of NO are widely accepted to be the 
primary cause for the significant loss of erectile function in diabetic men. Although the 
pathophysiology of diabetic induced ED is multifactorial, I believe that the most 
important factors are related to a reduction in NO production from dysfunctional nitrergic 
nerves and reduced NO bioavailability through the generation of AGEs and oxygen free 
radicals. 
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PDE5 inhibitors require endogenous NO in order to produce relaxation of smooth 
muscle in the penis (Cashen et al., 2002). It has therefore been postulated that the reduced 
rate of success of PDE5 inhibitors in diabetic men (Rendell et al., 1999;Stuckey et al., 
2003) may be due to lower NO production from the endothelium and nerves of these 
men. 
To test this hypothesis, new therapeutic targets which are potentially able to 
induce relaxation independent of endogenous NO (BAY 41-2272 and NCX-911) were 
compared in control and diabetic tissues versus the PDE5 inhibitor sildenafil.    
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The effect of sildenafil, NCX-911 and BAY 41-2272 on the anococcygeus muscle 
It has previously been suggested that compounds which do not require 
endogenous NO would be more successful than PDE5 inhibitors to relax penile smooth 
muscle in diabetes (Cellek et al., 2002). The two compounds I used (NCX-911 and 
BAY41-2272) fit this description. NCX-911 has been previously shown to release NO 
spontaneously and increase cGMP concentrations by activating sGC and inhibiting PDE5 
(Seidler et al., 2002). Furthermore, NCX-911 has been shown to increase cGMP in a 
concentration-dependent manner in the absence of endogenous NO whereas sildenafil has 
little effect on cGMP concentrations under the same conditions (Seidler et al., 2002). As 
previously discussed, in a hypercholesterolemia rabbit model, NCX-911 was shown to be 
5-10 times more potent than sildenafil at reducing the phenylephrine-induced vascular 
tone (Riffaud JP, 2001).  BAY41-2272 is a non-NO-based compound (does not release 
NO) which activates sGC (Stasch et al., 2001). This activation does not require 
endogenous NO however the potency of the compound is elevated if there is endogenous 
NO in the environment. I previously showed that BAY41-2272 potentiates the nitrergic 
responses in the rabbit corpus cavernosum.  
In my study, in control (non-diabetic) tissues BAY41-2272 (EC50 = 151.6±9.2 nM) 
was significantly more potent at relaxing anococcygeal tissues pre-contracted with 
phenylephrine compared to both NCX-911 and sildenafil. However, there was no 
significant difference between the NCX-911 and sildenafil (EC50 = 1088.8±165 nM and 
827.1±167.3 nM respectively). The EC50 for sildenafil in this study however was 
significantly different from that of a previous study in the anococcygeus of mice (EC50 = 
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30 nM) (Frith and Gibson, 2000). This may be accounted for by differences in 
methodology i.e. use of carbachol and species differences i.e. mouse versus rat. 
I compared BAY41-2272 and NCX-911 to sildenafil with respect to their potency 
to relax the anococcygeus muscle of diabetic rats. I found that the potency of BAY 41-
2272 and NCX-911 was not altered by diabetes whereas sildenafil was significantly less 
potent in the diabetic group. This suggests that compounds which do not require 
endogenous NO to relax the penile smooth muscle could be more efficacious than PDE5 
inhibitors in the treatment of ED in diabetic men.  
In contrast, a previous study reported that relaxation of the corpus cavernosum to 
exogenous NO donors and endogenous nitrergic nerve stimulation was enhanced by 
sildenafil with same potency in the control and the diabetic group in rabbit corpus 
cavernosum (Thompson et al., 2001). Although the authors did not study the effect of 
sildenafil on phenylephrine-induced tone in that study, they noted that their model 
represented only the early phases of autonomic neuropathy and suggested that the 
potency of sildenafil might be decreasing in the later phases. Furthermore, it has been 
recently shown that severe nitrergic degeneration starts after 12 weeks of diabetes in the 
rat model (Cellek et al., 2003) in contrast to earlier studies which showed that there was 
no loss of NOS content up to 8 weeks (Way et al., 1999). The decrease in the potency of 
sildenafil seen in this study may therefore be dependent on the severity of nitrergic nerve 
loss, which is time-dependent in diabetic animal models. 
In this study, although the EC50 value for sildenafil was higher in the diabetic 
group than in the control group, Emax values were similar. Hence the shift in the 
concentration–response curve was parallel, suggesting that the target (PDE5) is still 
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active but its sensitivity was altered during diabetes. This may be explained by either the 
enzyme was desensitised or the substrate of the enzyme (cGMP) was less available. Since 
there was no shift in the curves to NCX-911 and BAY41-2272, the desensitisation 
possibility is doubtful and it is more likely that the available NO-cGMP input is reduced 
in diabetes. Although there was no significant difference between the potencies of NCX-
911 and sildenafil in control tissues, the difference became significant in diabetic animals, 
suggesting that NO supplied by NCX-911 accounted for the preserved relaxant effect in 
diabetic tissue. In the control tissues, NO released from NCX-911 did not cause any 
additional relaxant effect probably because endogenous NO was higher than the NO 
released by NCX-911. A comparative measurement of NO released from NCX-911 and 
nitrergic nerves locally would be required to support this theory.  
Interestingly I found that NCX-911 and sildenafil failed to potentiate the 
remaining nitrergic relaxation responses in the diabetic group. This suggests that a 
threshold concentration of endogenous NO might be required to stimulate the cGMP 
pathway. When the endogenous NO levels are below this threshold, PDE5 inhibitors are 
potentially without effect. In the long-term diabetes model I used, NO production is 
reported to be so low (Cellek et al., 2003) that even in the presence of an NO-releasing 
compound (e.g. NCX-911), the threshold may not be reached. Therefore, the compounds 
fail to potentiate the remaining nitrergic response. However, further studies measuring 
cGMP concentrations are required to confirm this. 
In the case of sGC activator BAY41-2272 however, the compound was able to 
potentiate the remaining nitrergic responses in the diabetic group. This could be due to 
the compound’s ability to synergise with the remaining very low levels of endogenous 
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NO. A similar phenomenon in the rabbit corpus cavernosum, where the inhibition of 
nitrergic responses with an inhibitor of NO synthase was reversed by BAY41-2272 was 
previously demonstrated (Kalsi et al., 2003).   
My results further confirm the different pharmacological profiles of these 
compounds. The systemic administration of NCX-911 and BAY41-2272 has been shown 
to be without major side effects (Bischoff et al., 2003;Riffaud JP, 2001), although at high 
doses both compounds can affect the systemic blood pressure (Riffaud JP, 2001;Stasch et 
al., 2001). Nevertheless, I believe that further research in higher animals with different 
durations of diabetes is required to compare the effects of similar compounds in the 
corpus cavernosum to further validate these results.  
In conclusion, in long-term diabetes with severe endogenous NO deficiency the 
NO-releasing sildenafil (NCX-911) and the sGC activator (BAY41-2272) have higher 
potency than sildenafil to relax the anococcygeus muscle. The reduction in nitrergic 
responses is reversed by BAY41-2272 but not by sildenafil and NCX-911. Further 
research is required to characterise the pharmacological profiles of these compounds in 
human tissue. 
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Update of sGC activators 
Following on from my results using the sGC activators YC-1 and BAY41-2272, 
the knowledge of the function of sGC has continued to increase as has the number of 
putative new agents. The available agents can now be divided into those which are NO-
independent but haem-dependent stimulators and those which are NO- and haem-
independent. 
 
Haem-dependent sGC stimulators 
In 1994, scientists at Bayer HealthCare AG started a search for substances that 
could induce an increase in NO dependent pathways by stimulating sGC.  This led to the 
discovery of 5-substituted-2-furaldehydehydrazone derivatives as direct NO-independent 
sGC stimulators. Unfortunately, the potency of these agents increased when exposed to 
light.  However, another group working in parallel, in 1994 described a structurally 
related compound, the indazole derivative YC-1 (Ko et al., 1994), which was 
subsequently characterized as an NO-independent, haem-dependent stimulator of highly 
purified sGC (Mulsch et al., 1997). Furthermore, its potency was unaffected by the 
prevailing light conditions (Friebe et al., 1996).  
More recently, various compounds that activate sGC in an NO-independent 
fashion have been identified (Lee et al., 2001;Selwood et al., 2001;Straub et al., 2001). 
These include BAY41–2272, BAY41–8543, CMF-1571 and A-350619 and now BAY 
63-2521. They are all haem-dependent sGC-stimulators as they share a crucial 
dependency on the presence of the reduced prosthetic haem moiety and strong synergistic 
enzyme activation when combined with NO. 
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Abbott laboratories developed the novel sGC activator A-350619. Activation of 
sGC by A-350619 was demonstrated to be partially inhibited by ODQ whereas pre-
treatment with N-omega-nitro-L-arginine, (an NO-synthase inhibitor) resulted in a dose-
dependent right ward shift in the dose-response curve in corporeal smooth muscle. 
Moreover, in their study the addition of sodium nitroprusside (SNP) was found to 
potentiate the relaxation effect of A-350619. Further work in a conscious rat model, also 
showed that A-350619 (1 mol/kg) could induce penile erection (Miller et al., 2003). 
In subsequent studies the same group of investigators, examined the effects of a 
derivative of acrylamide (A-778935) ((+/-)-cis-3-[2-(2,2-dimethyl-propylsulfanyl)-
pyridin-3-yl]-N-(3-hydroxy-c yclohexyl)-acrylamide) on corpus cavernosal smooth 
muscle. A-778935 was found to activate sGC synergistically with SNP over a wide range 
of concentrations, inducing up to 420-fold activation. Once again ODQ was found to 
competitively inhibit the activation by A-778935. There was no reported activation of 
haem-deficient sGC, indicating that the activation of sGC by A-778935 is fully haem-
dependent. A-778935 was also found to increase intracellular cGMP levels 
concentration-dependently in smooth muscle. However, in the presence of 1 M SNP, a 
lower concentration of A-778935 was required to increase cGMP versus A-778935 alone. 
A-778935 was reported to relax cavernosal tissue strips in a concentration-dependent 
manner. The addition of 1 M SNP resulted in shifting the concentration-response curve 
to the left and increased potency (Nakane et al., 2006). 
CFM-1571 was developed using YC-1 as a lead structure (Selwood et al., 2001). 
CFM-1571 has been shown to be a weak but specific activator of sGC (EC50 =5.5 M) 
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that inhibits platelet aggregation (EC50 = 2.8 M). Similar to YC-1, it reportedly 
synergizes with NO however unlike YC-1 it does not show PDE inhibitory activity and 
demonstrates minimal inhibition of NOS (Selwood et al., 2001). 
More recently, Bayer has developed a further pyrazolopyridine derivative, BAY 
41-8543 (Stasch et al., 2002a;Straub et al., 2002). It has been reported to act in a similar 
mode of action to that of YC-1, but demonstrates an improved potency and specificity for 
sGC (Stasch et al., 2002a;Straub et al., 2002). It has been proposed that in the absence of 
NO, BAY41-2272 stimulates sGC activity approximately 20-fold from baseline (Stasch 
et al., 2001) whereas BAY41-8543 exhibits even greater potency stimulating sGC 
activity up to 92-fold (Stasch et al., 2002a). Furthermore, BAY41-8543 has also been 
shown to have about a 3-fold greater potency than BAY41-2272 in various in vitro and in 
vivo assays (Stasch et al., 2002a;Straub et al., 2002). Like BAY41-2272, it is now known 
that it synergizes with NO. By stabilizing the nitrosyl-haem complex it is able to 
stimulate sGC activity up to 200-fold (Schmidt et al., 2003). Furthermore, it also does not 
cause inhibition of PDE5 (Schermuly et al., 2008;Stasch et al., 2002a). Moreover, 
BAY41-8543 has no appreciable inhibitory effect on other cGMP specific PDEs, such as 
PDE1, 2 and 9 (Stasch et al., 2002a) (Bischoff and Stasch, 2004). 
In-vitro studies also confirm that BAY41-8543 like BAY41-2272, exerts potent 
vasodilatory, anti-platelet, and anti-proliferative activity (Stasch et al., 2002a). The 
vasodilatory effects of BAY41-2272 and BAY41-8543 have been observed in isolated 
systemic, aortic, coronary, and pulmonary arteries and veins, and the compounds potently 
reduce coronary perfusion pressure in the rat heart Langendorff preparation without any 
effect on left ventricular pressure and heart rate (Hobbs, 2002;Stasch et al., 2001;Stasch 
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et al., 2002a). Interestingly, BAY41-8543 has also been reported to stimulate equivalent 
degrees of vasodilatation in normal and nitrate-tolerant systems (Stasch et al., 2002a), 
which suggests that it may be devoid of the problem of tachyphylaxis. 
BAY63-2521 is the most recent of the optimised compounds following extensive 
pharmacological and pharmacokinetic profiling of additional compounds in pre-clinical 
tests (Evgenov et al., 2006;Stasch et al., 2002a). BAY63-2521 has been shown to 
stimulate sGC activity up to 73-fold in vitro in a concentration-dependent manner and 
synergize with the NO donors to increase sGC activity up to 112-fold (Schermuly et al., 
2008). BAY63-2521 has been reported to possess vasodilatory properties similar to 
BAY41-8543 in vitro and in vivo. It has been demonstrated to inhibit contraction of 
rabbit aortic rings, rabbit saphenous artery rings, porcine coronary artery rings, canine 
femoral vein rings, and rabbit corpus cavernosum. Furthermore, BAY63-2521 promotes  
smooth muscle relaxation in arteries isolated from nitrate-tolerant rabbits, and decreases 
acute pulmonary vasoconstriction in isolated mouse lungs at a concentration of 0.01 M 
(Schermuly et al., 2008).  Moreover, similar to other novel sGC activators, at 
concentrations up to 10 M, BAY63-2521 does not inhibit PDEs 1, 2, 5 or 9 (Schermuly 
et al., 2008). This compound has now undergone Phase I trials (Frey et al., 
2008;Grimminger et al., 2009), and Phase II trials are currently in progress. 
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Haem-independent sGC activators 
Using a cell-based assay for cGMP as a screening tool, more than 900,000 
compounds were screened. This lead to the identification of the primary hit BAY W 1449, 
an amino dicarboxylic acid (Stasch et al., 2002a;Wunder et al., 2005). Further 
modifications resulted in BAY58–2667 to be selected in 2002 as the first NO-
independent activator of sGC. This compound showed a completely different range of 
characteristics to any of the known haem-dependent sGC stimulators. The activation of 
sGC by this compound was even stronger after oxidation or removal of the prosthetic 
haem group, indicating a previously unknown mechanism of enzyme activation (Stasch et 
al., 2002b).  
 
Sanofi-Aventis have also developed compounds with comparable characteristics. 
They are anthranilic acid derivatives 5-chloro-2-(5-chloro-thiophene-2-sulfonylamino-N-
(4-(morpholine-4-sulfonyl)-phenyl)-benzamide sodium salt (HMR1766) and 2-(4-chloro-
phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-
benzamide (S3448). Both compounds have been shown to activate sGC in a 
concentration-dependent manner (EC50 = 0.5–10 µM). Once again the activation of sGC 
by these compounds was synergistic with NO donors. However, instead of being 
inhibited, they were found to be potentiated by the haem-iron oxidant 1H-[1,2,4]-
oxdiazolo[3,4-a]quinoxalin-1-one (ODQ). This suggests that these compounds target the 
ferric- haem sGC complex. Furthermore, it was reported that protoporphyrin IX was 
found to act as a competitive activator, and zinc-protoporphyrin IX as an inhibitor of 
activation of haem-oxidized sGC by HMR1766 and S3448. Haem depletion of sGC by 
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Tween 20 treatment was demonstrated to reduce activation. Furthermore both compounds 
increased cGMP levels in cultured rat aortic smooth muscle cells; induced relaxation of 
isolated endothelium-denuded rat aorta, porcine coronary arteries, and human corpus 
cavernosum (EC50 1 to 10 µM) and elicited phosphorylation of the cGMP kinase 
substrate vasodilator-stimulated phosphoprotein at Ser239. An intravenous HMR1766 
injection resulted in a decrease in arterial blood pressure in anesthetized pigs. All of these 
pharmacological responses to the new compounds were enhanced by sGC inhibitors 
(ODQ and NS2028). These findings suggest that HMR1766 and S3448 preferentially 
activate the NO-insensitive haem-oxidized form of sGC. This form of sGC may therefore 
be used as a pharmacological target for newer types of vasodilator drugs (Schindler et al., 
2006). 
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Further strategies for the treatment of ED 
ED is usually the result of a number of processes acting either in parallel or together to 
result in a significant reduction in bioavailability of the chief mediator of erection, NO. I 
believe that future strategies for the treatment of ED should be aimed at correcting or 
treating the underlying mechanisms involved in the pathogenesis ED as well as finding 
more specific and effective sGC activators and NO-releasing compounds.  
The various targets of investigation include gene therapy with neurotrophic 
factors, eNOS, nNOS and superoxide dismutase. Through the use of an appropriate 
vector, diabetic animals have already been successfully transfected with these agents. It 
has been reported that direct injections into the cavernous sheath of diabetic rats with 
neurotropohin-3 (NT3) using the herpes simplex virus as the vector have been performed. 
Subsequent immuno-reactive stains have demonstrated a significant increase in nNOS 
neurons in the major pelvic ganglia. Moreover, this was associated with significant 
increases in the cavernous nerve induced  rises in the intracavernous pressure (Bennett et 
al., 2005).  
Moreover, diabetic rats which were injected with adenoviruses containing eNOS 
into their corpus cavernosum, have seen subsequent significant rises in intracavernous 
pressures  secondary to cavernous nerve stimulation. This was further associated with a 
rise in eNOS (measured by western blot analysis) and an increase in NOS biosynthesis 
(measured by an increase in cavernous nitrate and nitrite formation) (Bivalacqua et al., 
2003).  
More recently, the intracavernous injection of adenoviruses containing superoxide 
dismutase into diabetic rats has been preformed. The results indicate a decrease in 
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superoxide anion levels, an increase in NO bioavailability and an increase in cGMP 
levels with ultimately an increase in intracavernous pressure demonstrated (Bivalacqua et 
al., 2005).  
In the field of ion channels, other work was performed using intracavernous 
injection of hSlo (calcium-sensitive potassium channel) in diabetic rats.  This resulted in 
increases in intracavernous pressures after cavernosal nerve stimulation compared with 
controls. These results were the basis for a potential alteration in these potassium 
channels secondary to diabetes (Christ et al., 1998).  
More recently, the effects of gene transfer on erectile function and sexual 
behaviour have evaluated in male cynomolgus monkeys with ED (Christ et al., 2008) and 
an ageing rat model (Melman et al., 2008). The animals were injected intracavernously  
with a smooth-muscle-specific gene transfer vector (pSMAA-hSlo) encoding the pore-
forming subunit of the human large-conductance, calcium-sensitive potassium channels 
(Maxi-K). The results report that were significant improvements in erectile function and 
sexual behaviour (Christ et al., 2008) or increased intracavernous pressure (ICP) 
responses to cavernous nerve stimulation (Melman et al., 2008) after the intracorporeal 
gene transfer. These results support the concept that intracorporeal Maxi-K-channel gene 
transfer may be a novel way of improving erectile function. 
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Conclusions 
 
1. The sGC activators BAY41-2272 and YC-1 cause potent relaxation of human and 
rabbit corpus cavernosum. Their effect synergizes with endogenous NO, however 
the potency of BAY 41-2272 is far superior to YC-1.  
 
2. In the total absence of endogenous NO, BAY41-2272 still potently relaxes the 
rabbit corpus cavernosum smooth muscle and reverses the inhibition of nitrergic 
relaxations in corpus cavernosum. 
 
3. The NO releasing PDE5 inhibitor (NCX-911) is a potent relaxant with a similar 
potency to NO and sildenafil. However, in contrast to sildenafil, it is equally 
effective with respect to relaxation of rabbit and human corpus cavernosum 
independent of NO availability suggesting release of NO as well as PDE5 
inhibition.  
 
4. NCX-911 like sildenafil potentiates both the duration and magnitude of the 
nitrergic relaxation, indicating a similar mechanism of action with respect to 
PDE5 inhibition.  
 
5. In the long-term diabetes model I used, there is a significant reduction in nitrergic 
function compared to controls.  
 
6. In this long-term diabetes animal model with severe endogenous NO deficiency, 
the NO-releasing sildenafil (NCX-911) and the sGC activator (BAY41-2272) had 
a significantly greater potency compared to sildenafil to relax the anococcygeus 
muscle.  
 
7. In this model, the reduction in nitrergic responses was reversed by BAY41-2272 
but not by sildenafil or NCX-911. This suggests that a threshold concentration of 
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endogenous NO is required to stimulate the cGMP pathway. When the 
endogenous NO levels are below this threshold, NCX-911 and sildenafil are 
without effect and fail to potentiate the remaining nitrergic response. However, 
further studies measuring cGMP concentrations are required to confirm this. 
 
8. PDE5 inhibitors such as sildenafil have reduced efficacy in diabetes. This is likely 
to be secondary to reduced endogenous NO production. I believe that for a PDE5 
inhibitor to be successful a certain degree of residual NO needs to be present.  
 
9. My results support the potential role of sGC activators and NO-releasing PDE5 
inhibitors as novel ways of treating male ED particularly where endogenous NO 
production is dysfunctional such as in severe diabetes. However, further research 
is required to characterise the pharmacological profiles of these compounds in 
higher animals and in humans. 
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2. International Index of Erectile Function Questionnaire (IIEF) 
These questions ask about the effects erection problems on the patient’s sex life, over the 
past 4 weeks. In answering these questions, the following definitions apply: 
Definitions: 
Sexual activity includes intercourse, caressing, foreplay and masturbation 
Sexual intercourse is defined as vaginal penetration of the partner (you entered the 
partner) 
Sexual stimulation includes situations like foreplay with a partner, looking at erotic 
pictures, etc. 
Ejaculate is defined as the ejection of semen from the penis (or the feeling of this) 
Mark ONLY one circle per question:  
1. Over the past 4 weeks, how often were you able to get an erection during sexual 
activity?  
0 No sexual activity  
1 Almost always or always  
2 Most times (much more than half the time)  
3 Sometimes (about half the time)  
4 A few times (much less than half the time)  
5 Almost never or never 
2. Over the past 4 weeks, when you had erections with sexual stimulation, how often 
were your erections hard enough for penetration?  
0 No sexual stimulation  
1 Almost always or always  
2 Most times (much more than half the time)  
3 Sometimes (about half the time)  
4 A few times (much less than half the time)  
5 Almost never or never 
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Questions 3, 4 and 5 will ask about erections you may have had during sexual 
intercourse. 
3. Over the past 4 weeks, when you attempted sexual intercourse, how often were you 
able to penetrate (enter) your partner?  
0 Did not attempt intercourse  
1 Almost always or always  
2 Most times (much more than half the time)  
3 Sometimes (about half the time)  
4 A few times (much less than half the time)  
5 Almost never or never 
4. Over the past 4 weeks, during sexual intercourse, how often were you able to maintain 
your erection after you had penetrated (entered) your partner? 
0 Did not attempt intercourse 
1 Almost always or always 
2 Most times (much more than half the time)  
3 Sometimes (about half the time)  
4 A few times (much less than half the time)  
5 Almost never or never 
5. Over the past 4 weeks, during sexual intercourse, how difficult was it to maintain your 
erection to completion of intercourse?  
1 Did not attempt intercourse  
2 Almost always or always  
3 Most times (much more than half the time)  
4 Sometimes (about half the time) 0 A few times (much less than half the time)  
5 Almost never or never 
6. Over the past 4 weeks, how many times have you attempted sexual intercourse?  
0 No attempts  
1 1-2 attempts  
2 3-4 attempts  
3 5-6 attempts  
4 7-10 attempts  
5 11 or more attempts 
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7. Over the past 4 weeks, when you attempted sexual intercourse how often was it 
satisfactory for you?  
0 Did not attempt intercourse  
1 Almost always or always  
2 Most times (much more than half the time)  
3 Sometimes (about half the time)  
4 A few times (much less than half the time)  
5 Almost never or never 
8. Over the past 4 weeks, how much have you enjoyed sexual intercourse?  
0 No intercourse  
1 Very highly enjoyable  
2 Highly enjoyable  
3 Fairly enjoyable  
4 Not very enjoyable  
5 Not enjoyable 
 
9. Over the past 4 weeks, when you had sexual stimulation or intercourse how often did 
you ejaculate?  
0 Did not attempt intercourse  
1 Almost always or always  
2 Most times (more than half the time)  
3 Sometimes (about half the time)  
4 A few times (much less than half the time)  
5 Almost never or never  
10. Over the past 4 weeks, when you had sexual stimulation or intercourse how often did 
you have the feeling of orgasm or climax (with or without ejaculation)? 
0 No sexual stimulation or intercourse 
1 Almost always or always 
2 Most times (much more than half the time) 
3 Sometimes (about half the time) 
4 A few times (much less than half the time) 
5 Almost never or never 
Questions 11 and 12 ask about sexual desire. Let's define sexual desire as a feeling that 
may include wanting to have a sexual experience (for example, masturbation or 
intercourse), thinking about having sex or feeling frustrated due to a lack of sex. 
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11. Over the past 4 weeks, how often have you felt sexual desire?  
5 Almost always or always  
4 Most times (much more than half the time)  
3 Sometimes (about half the time)  
2 A few times (much less than half the time)  
1 Almost never or never 
12. Over the past 4 weeks, how would you rate your level of sexual desire?  
5 Very high  
4 High  
3 Moderate  
2 Low  
1 Very low or none at all 
13. Over the past 4 weeks, how satisfied have you been with you overall sex life?  
5 Very satisfied  
4 Moderately satisfied  
3 About equally satisfied and dissatisfied  
2 Moderately dissatisfied  
1 Very dissatisfied 
14. Over the past 4 weeks, how satisfied have you been with your sexual relationship 
with your partner? 
5 Very satisfied 
4 Moderately satisfied 
3 About equally satisfied and dissatisfied 
2 Moderately dissatisfied 
1 Very dissatisfied 
15. Over the past 4 weeks, how do you rate your confidence that you can get and keep 
your erection? 
5 Very high 
4 High 
3 Moderate  
2 Low  
1 Very low 
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Scoring Algorithm for IIEF 
All items are scored in 5 domains as follows: 
Domain Items Range Score Max Score 
Erectile Function  1, 2, 3, 4, 5, 15   0-5 30 
Orgasmic Function 9, 10  0-5 10 
Sexual Desire  11, 12  0-5 10 
Intercourse 
Satisfaction 6, 7, 8  0-5 15 
Overall Satisfaction 13, 14  0-5 10 
Clinical Interpretation 
I. Erectile function total scores can be interpreted as follows: 
Score Interpretation 
0-6 Severe dysfunction 
    
7-12 Moderate dysfunction 
    
13-18 Mild to moderate dysfunction 
    
19-24 Mild dysfunction 
    
25-30  No dysfunction 
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II. Orgasmic function total scores can be interpreted as follows: 
Score Interpretation 
0-2 Severe dysfunction 
    
3-4 Moderate dysfunction 
    
5-6 Mild to moderate dysfunction 
    
7-8 Mild dysfunction 
    
9-10 No dysfunction 
    
III. Sexual desire total scores can be interpreted as follows: 
Score Interpretation 
0-2 Severe dysfunction 
    
3-4 Moderate dysfunction 
    
5-6 Mild to moderate dysfunction 
    
7-8 Mild dysfunction 
    
9-10 No dysfunction 
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IV. Intercourse satisfaction total scores can be interpreted as follows: 
Score Interpretation 
0-3 Severe dysfunction 
    
4-6 Moderate dysfunction 
    
7-9 Mild to moderate dysfunction 
    
10-12 Mild dysfunction 
    
13-15 No dysfunction 
    
V. Overall satisfaction total scores can be interpreted as follows: 
Score Interpretation 
0-2 Severe dysfunction 
    
3-4 Moderate dysfunction 
    
5-6 Mild to moderate dysfunction 
    
7-8 Mild dysfunction 
    
9-10 No dysfunction 
    
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A.  
The international index of erectile function (IIEF) a multidimensional scale for 
assessment of erectile dysfunction. Urology. 1997 Jun; 49(6):822-30. 
